PIH2 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION FOLLOWING HYSTERECTOMY (Englisch)
- Neue Suche nach: Leaper, D.J.
- Neue Suche nach: Holy, C.E.
- Neue Suche nach: Chen, B.P.
- Neue Suche nach: Ghosh, E.
- Neue Suche nach: Edmiston, C.E.
- Neue Suche nach: Leaper, D.J.
- Neue Suche nach: Holy, C.E.
- Neue Suche nach: Chen, B.P.
- Neue Suche nach: Ghosh, E.
- Neue Suche nach: Edmiston, C.E.
In:
Value in health
;
21
, 3
;
S214
;
2018
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:PIH2 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION FOLLOWING HYSTERECTOMY
-
Beteiligte:Leaper, D.J. ( Autor:in ) / Holy, C.E. ( Autor:in ) / Chen, B.P. ( Autor:in ) / Ghosh, E. ( Autor:in ) / Edmiston, C.E. ( Autor:in )
-
Erschienen in:Value in health ; 21, 3 ; S214
-
Verlag:
- Neue Suche nach: Elsevier Science B.V., Amsterdam
-
Erscheinungsdatum:01.01.2018
-
Format / Umfang:S214
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Englisch
- Neue Suche nach: 610.28
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
DDC: 610.28 -
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 21, Ausgabe 3
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 249
-
Affordability of New Technologies: The Next FrontierTowse, Adrian / Mauskopf, Josephine A. et al. | 2018
- 252
-
Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and CuresDanzon, Patricia M. et al. | 2018
- 258
-
The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care ValuePearson, Steven D. et al. | 2018
- 266
-
Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget ImpactsLomas, James / Claxton, Karl / Martin, Stephen / Soares, Marta et al. | 2018
- 276
-
Paying for Cures: Perspectives on Solutions to the "Affordability Issue"Schaffer, Sarah Karlsberg / Messner, Donna / Mestre-Ferrandiz, Jorge / Tambor, Ellen / Towse, Adrian et al. | 2018
- 280
-
Affordability of Health Care: A Global CrisisWatkins, John B. et al. | 2018
- 283
-
Estimating the Learning Curve of a Novel Medical Device: Bipolar Sealer Use in Unilateral Total Knee ArthroplastiesKuznietsova, Victoria / Woodward, Robert S. et al. | 2018
- 295
-
Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational StudyRapp, Thomas / Andrieu, Sandrine / Chartier, Florence / Deberdt, Walter / Reed, Catherine / Belger, Mark / Vellas, Bruno et al. | 2018
- 304
-
Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer PatientsZhong, Yue / Valderrama, Adriana / Yao, Jianying / Donga, Prina / Bilir, Pinar / Neumann, Peter J. et al. | 2018
- 310
-
Cost-Effectiveness of Antibiotic Prophylaxis Strategies for Transrectal Prostate Biopsy in an Era of Increasing Antimicrobial ResistanceLee, Kyueun / Drekonja, Dimitri M. / Enns, Eva A. et al. | 2018
- 318
-
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney DiseaseHabbous, Steven / Przech, Sebastian / Martin, Janet / Garg, Amit X. / Sarma, Sisira et al. | 2018
- 326
-
Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?Malone, Daniel C. / Brown, Mary / Hurwitz, Jason T. / Peters, Loretta / Graff, Jennifer S. et al. | 2018
- 334
-
Sensitivity of Claims-Based Algorithms to Ascertain Smoking Status More Than Doubled with Meaningful UseHuo, Jinhai / Yang, Ming / Tina Shih, Ya-Chen et al. | 2018
- 341
-
What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10, 000/QALY?Carroll, Christopher / Houten, Rachel / Boland, Angela / Kaltenthaler, Eva / Dickson, Rumona et al. | 2018
- 351
-
The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of HypertensionPeñaloza-Ramos, Maria Cristina / Jowett, Sue / Sutton, Andrew John / McManus, Richard J. / Barton, Pelham et al. | 2018
- 364
-
Associations of Smoking, Physical Inactivity, Heavy Drinking, and Obesity with Quality-Adjusted Life Expectancy among US Adults with DepressionJia, Haomiao / Zack, Matthew M. / Gottesman, Irving I. / Thompson, William W. et al. | 2018
- i
-
Table of Contents| 2018
- S2
-
CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALSRamos, M. / Foos, V. / Ustyugova, A.V. / Hau, N. / Gandhi, P. / Lamotte, M. et al. | 2018
- S3
-
CN2 - PREDICTING UTILITY SCORES IN LOCALIZED PROSTATE CANCER: MAPPING FROM EPIC TO PORPUSZamora, V. / À, Pont / Garin, O. / Pardo, Y. / Ferrer Fores, M. et al. | 2018
- S4
-
CN6 - COST-EFFECTIVENESS MODEL OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE (FLT3+) ACUTE MYELOID LEUKEMIA (AML): A FRENCH PERSPECTIVECariou, C. / Tremblay, G. / Dolph, M. / Brandt, P.S. / Forsythe, A. et al. | 2018
- S5
-
CP4 - WEIGHTED AVERAGE CALCULATIONS FOR POPULATING COST-EFFECTIVENESS MODELS: HOW IGNORING THE MODEL'S CLINICAL PATHWAYS CAN SIGNIFICANTLY BIAS THE INCREMENTAL COST-EFFECTIVENESS RATIO (ICER)Van Vlaenderen, I. / Moeremans, K. / Van Bellinghen, L. et al. | 2018
- S6
-
DB1 - GLYCAEMIC CONTROL, CARDIOVASCULAR DISEASE AND MORTALITY IN TYPE 2 DIABETES (T2D) PATIENTS IN A REAL LIFE SETTING OVER TIME: POPULATION-BASED DATA FROM THE NETHERLANDSHouben, E. / Heintjes, E. / Cremers, S. / Beekman, W. / Beest F, Penning-van / Stehouwer, C. / Herings, R. et al. | 2018
- S8
-
HT3 - DESCRIPTION AND COMPARISON OF EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENTPisarczyk, K. / Hajjeji, B. / Rémuzat, C. / Espín, J. / Toumi, M. et al. | 2018
- S9
-
HT8 - DOES IQWIG MATTER? FREQUENCY OF DIVERGENT OPINIONS BETWEEN IQWIG AND THE G-BAMacaulay, R. / Mohamoud, Z. / Schmidt, B. et al. | 2018
- S10
-
MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMABlommestein, H. / van Beurden-Tan, C. / de Groot, S. / Blijlevens, N. / Sonneveld, P. / Groot CA, Uyl-de / Zweegman, S. / Franken, M.G. et al. | 2018
- S11
-
ND2 - FUNCTIONAL LOSS ACROSS STAGES OF ALZHEIMER'STsong, W. / Jones, E. / Pike, J. / Bluff, D. et al. | 2018
- S12
-
PP4 - ONE SIZE DOES NOT FIT ALL: HETEROGENEOUS PATIENT PREFERENCES AND TRADEOFFS FOR ANTIRETROVIRAL THERAPY - RESULTS OF A DISCRETE CHOICE EXPERIMENTOstermann, J. / Derrick, C. / Yelverton, V. / Hobbie, A. / Weinhold, A. / Thielman, N. et al. | 2018
- S15
-
PCN5 - TREATMENTS OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER IN ROUTINE CLINICAL PRACTICE – A SYSTEMATIC REVIEWBhutani, M.K. / Rajora, P. / Soni, D. / Pan, J.J. et al. | 2018
- S16
-
PCN10 - ECONOMIC IMPACT OF MEDICATION ERRORS DETECTED IN ONCOLOGIC INPATIENTS AND OUTPATIENTS IN A MEXICAN HOSPITALMorales Perez, M. / Paladio-Hernandez, J.A. / Luna Mendoza, D. / Paredes-Garcia, P. / Munguia Juarez, L. / Sanchez Rodriguez, I. / Lopez-Luis, J. / Hernandez-Martinez, J. / Ramirez-Padilla, L. / Diaz-Rosales, S. et al. | 2018
- S17
-
PCN17 - INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMARoskell, N. / Gregory, J. / Wisniewski, T. / Thompson, G.J. / De la Cruz, C. et al. | 2018
- S18
-
PCN23 - EFFICIENCY OF NIVOLUMAB TREATMENT AFTER PLATINUM CHEMOTHERAPY IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN SPAINSuarez, J. / Juarez-Garcia, A. / Shaw, J.W. / Contente, M. / Polanco, C. et al. | 2018
- S19
-
PCN30 - EVIDENCE GENERATION IN A EARLY ACCESS STRATEGY FOR TARGETED ONCOLOGY THERAPIES: A COMPARISON IN NON-SMALL CELL LUNG CANCERvan Hooijdonk, I.E. / Lai, L. / van Engen, A. et al. | 2018
- S20
-
PCN37 - MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF APALUTAMIDE AND ENZALUTAMIDE IN THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCERChowdhury, S. / Oudard, S. / Hadaschik, B.A. / Uemura, H. / Joniau, S. / Pilon, D. / Ladouceur, M. / Behl, A. / Liu, J. / Dearden, L. et al. | 2018
- S21
-
PCN43 - A TARGETED REVIEW OF NICE SINGLE TECHNOLOGY APPRAISALS (STAS) IN UROTHELIAL CANCER SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)Adedokun, L. / Penaloza-Ramos, C. / Lee, J. et al. | 2018
- S22
-
PCN53 - STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORSLorenzi, M. / Amonkar, M. / Zhang, J. / Mehta, S. / Liaw, K. et al. | 2018
- S23
-
PCN58 - MEDIAN SURVIVAL, MEAN SURVIVAL OR HAZARD RATIO: WHICH ENDPOINT IS THE MOST APPROPRIATE FOR PATIENTS, PHYSICIANS AND POLICY MAKERS?Ben-Aharon, O. / Magnezi, R. / Leshno, M. / Goldstein, D.A. et al. | 2018
- S25
-
PCN70 - ASSESSING THE BUDGET IMPACT OF INCLUDING SUNITINIB FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ARGENTINAMacmullen, M. et al. | 2018
- S26
-
PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEMKashiura, D. / Souza, P.V. / Garrido, S.D. / Nardi, E. / Alves, M. et al. | 2018
- S27
-
PCN80 - BUDGET IMPACT ANALYSIS WITH USE OF SUBCUTANEUS TRASTUZUMABPoquet-Jornet, J.E. / Carrera Hueso, J. / Crespo, C. / Cuesta-Grueso, C. / Ramón Barrios, M.A. / Gasent-Blesa, J.M. / Fortuny-Organs, B. et al. | 2018
- S30
-
PCN96 - INITIAL THERAPY FOR ADVANCED PROSTATE CARCINOMA (PCA) WITH A GNRH AGONIST (GNRHA) AND ANTAGONISTS - A RETROSPECTIVE ANALYSIS OF PRESCRIPTION PATTERNS AND HOSPITAL COSTS BASED ON GERMAN GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY HEALTH INSURANCE)] DATAHupe, M.C. / Hammerer, P. / Ketz, M. / Kossack, N. / Colling, C. / Merseburger, A.S. et al. | 2018
- S31
-
PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALYAgirrezabal, I. / Gaikwad, I. / Cirillo, L. / Lothgren, M. et al. | 2018
- S32
-
PCN108 - TARGETED LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN UROTHELIAL CARCINOMAShah, M.V. / McGovern, A. / Hepp, Z. et al. | 2018
- S34
-
PCN121 - BSC COST IN TERMINAL CANCER PATIENTS IN KOREAPark, M. et al. | 2018
- S37
-
PCN138 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER IN ENGLANDTsoumani, E. / D'Oca, K. / Zhong, Y. / Prabhu, V.S. / Xu, R. / Li, H. et al. | 2018
- S38
-
PCN143 - HEALTH ECONOMIC EVALUATION OF BIOLOGIC AGENTS FOR METASTATIC COLORECTAL CANCER PATIENTS IN BRAZILCarvalho, A.C. / Cao, Q. / van Asselt, A. / Sasse, A.D. / Postma, M.J. et al. | 2018
- S39
-
PCN148 - COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB COMPARED TO TREATMENT OPTIONS FOR ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER PRIOR CHEMOTHERAPY - UPDATED RESULTSKourkoulas, N. / Athanasakis, K. / Kakouros, M. / Skroumpelos, A. / Kyriopoulos, J. et al. | 2018
- S40
-
PCN153 - COST-EFFECTIVENESS ANALYSIS OF APALUTAMIDE FOR TREATMENT IN NON- METASTASIS CASTRATION-RESISTANT PROSTATE CANCERZhou, Z. / Hu, X. et al. | 2018
- S41
-
PCN163 - COST-EFFECTIVENESS OF ADD-ON PERTUZUMAB COMBINED WITH TRASTUZUMAB AND DOCETAXEL VERSUS PLACEBO AS TREATMENT OF HER-2 POSITIVE METASTATIC BREAST CANCER IN CZECH REPUBLICDoležel, J. / Pour, M. / Skalický, D. / Fínek, J. et al. | 2018
- S42
-
PCN169 - A FLEXIBLE OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR METASTATIC EGFR+ NON-SMALL CELL LUNG CANCERJansen, J.P. / Incerti, D. / Shafrin, J. / Frederickson, A.M. / Lakdawalla, D.N. / Reckamp, K.L. et al. | 2018
- S43
-
PCN174 - NEPA, AN ORAL FIXED COMBINATION OF NETUPITANT AND PALONOSETRON, IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN GERMANY AND GREECEBourhis, F. / Eriksson, J. / Ruffo, P. / D'Agostino, P. / Turini, M. et al. | 2018
- S44
-
PCN179 - THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT ERYTHROPOIESIS-STIMULANTIG AGENTS FOR MANAGING CHEMOTHERAPY-INDUCED ANEMIA IN ADULT CANCER PATIENTS IN ACTUAL PRACTICE IN RUSSIAKrysanova, V. / Krysanov, I. / Ermakova, V. et al. | 2018
- S46
-
PCN192 - ROBOTIC VERSUS LAPAROSCOPIC DISTAL PANCREATECTOMY: A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS ANALYSISNuñez Alfonsel, J. / Ielpo, B. / Quijano, Y. / Vicente, E. / Hidalgo, A. et al. | 2018
- S47
-
PCN199 - HOW DO QUALITY-ADJUSTED LIFE YEARS IMPACT REIMBURSEMENT DECISION-MAKING IN THE UK?Farinella, M. / Rubinstein, J. / Inumerable, R.V. / Gizaw, N. / Ho, Y. et al. | 2018
- S48
-
PCN204 - A SYSTEMATIC REVIEW OF BARRIERS AND FACILITATORS TO PARTICIPATION IN SHARED DECISION MAKING IN CANCER CARE: AN INTERNATIONAL PERSPECTIVEKamal, K.M. / Covvey, J.R. / Mehta, Z. / Zacker, C. et al. | 2018
- S49
-
PCN210 - USING REAL WORLD DATA TO DETERMINE HEALTH SYSTEM COSTS OF A 5-YEAR NON-SMALL CELL LUNG CANCER COHORTSeung, S.J. / Hurry, M. / Walton, R.N. / Evans, W.K. et al. | 2018
- S50
-
PCN216 - CONTEMPORARY REAL-WORLD EVIDENCES ON ALK+ NSCLC PATIENTS IN ITALYTucci, C. / Trimarchi, C. / Urbinati, D. / Demma, F. / Fico, M. / Fioravanti, L. et al. | 2018
- S51
-
PCN221 - STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER TREATMENT PATTERNS AND COSTS: AN ONTARIO, CANADA ANALYSISSeung, S.J. / Hurry, M. / Walton, R.N. / Evans, W.K. et al. | 2018
- S52
-
PCN227 - ACCESS TO ESSENTIAL ANTINEOPLASTICS AND IMMUNOSUPPRESSIVESKazaryan, I. / Sevikyan, A. / Amirkhanyan, A. / Melikyan, M. et al. | 2018
- S53
-
PCN232 - VARIATION IN ACCESS TO PD-1 IMMUNOTHERAPIES IN EUROPELast, V. / Hickey, D.A. et al. | 2018
- S55
-
PCN245 - WHAT DRUGS SHOULD BE IN THE FOCUS OF COMPLEX EVALUATION IN PATIENTS WITH BREAST CANCER IN MOSCOWTolkushin, A. / Davydovskaya, M. / Ermolaeva, T. / Kokushkin, K. / Poliakova, K. et al. | 2018
- S56
-
PCN250 - ASSESSING THE REAL WORLD USAGE OF PD-1 INHIBITORS IN ADVANCED MELANOMA ACROSS EU5Rider, A. / Lewis, K. / Higson, O. et al. | 2018
- S58
-
PCN263 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH PROSTATE CANCER IN SPAIN.Solozabal, M. / De Prado, A. / Planellas, L. / Á, Baltasar-Sanchez / Carreño-Serra, A. / Callejo-Velasco, D. et al. | 2018
- S59
-
PCN268 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) FOLLOWING INITIAL PLATINUM THERAPY IN THE UNITED KINGDOMParikh, R.C. / Kurosky, S. / Kaye, J.A. / Levine, C. / Hettle, R. / Shire, N. / Mann, H. / Wang, H. et al. | 2018
- S60
-
PCN274 - TIME TO PRICE CHANGE FOLLOWING HTA DECISIONSLiden, D. / Jao, R. / Adler, B.N. / Lockwood, C. / Reinaud, F. et al. | 2018
- S61
-
PCN280 - IMPACT OF SUBOPTIMAL CLINICAL EVIDENCE ON HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONSZou, D. / Desrosiers, N. / Wu, S. / Prawitz, T. / Tervonen, T. / Marsh, K. / Caro, J.J. et al. | 2018
- S62
-
PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIAOmelyanovskiy, V. / Avxentyeva, M. / Sura, M. / Savilova, A.G. / Khachatryan, G.R. et al. | 2018
- S63
-
PCN292 - CANCER DRUGS IN GERMANY: HTA DECISIONS OF NEW AND INNOVATIVE ONCOLOGY DRUGS IN GERMANY – AN ANALYSIS USING THE PRISMACCESS® DATABASEMayer, F. / Hodek, J. / Walzer, S. et al. | 2018
- S64
-
PCN298 - MANAGEMENT OF ANTIEMETIC TREATMENT FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV): PATIENTS', ONCOLOGISTS' AND NURSES' PERSPECTIVESDuracinsky, M. / Chassany, O. / Griffith, J. / Coblentz-Baumann, L. et al. | 2018
- S65
-
PCN303 - ASSESSING THE VALUE OF NOVEL IMMUNO-ONCOLOGY (I-O) THERAPIES: HOW CONSISTENT IS THE HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES' CONSIDERATION OF THE SURVIVAL BENEFIT IN THE ABSENCE OF LONG-TERM DATA?Jonsson, B. / Chao, D. / Toumi, M. / Child, A. / Morris, J. / Hertel, N. et al. | 2018
- S66
-
PCN310 - SURVIVAL IN CANCER CLINICAL TRIALS: A COMPARISON OF EMA APPROVALS AND NICE RECOMMENDATIONS.Filby, A. / Edwards, H.K. / Beggs, L. / O'Brien, S. et al. | 2018
- S67
-
PCN315 - IMPACT OF PRO DATA ON IQWIG BENEFIT RATINGS IN ONCOLOGYLie, X. / Kempf, L. / van Engen, A. et al. | 2018
- S68
-
PCN321 - COMPARISON OF RECOMMENDATIONS FOR CANCER DRUGS CARRIED OUT BY THREE HTA BODIES (2015-2018): NICE TECHNOLOGY APPRAISALS, GERMAN FEDERAL JOINT COMMITTEE AND SPANISH THERAPEUTIC POSITIONING REPORTRebollo, P. / Hashim, M. / Gottschalk, F. / Ortega, T. / Heeg, B. / Wilke, T. et al. | 2018
- S69
-
PCN326 - COMPARATIVE ANALYSIS OF ESMO MAGNITUDE OF CLINICAL BENEFIT SCALE VALUES ASSIGNED TO NSCLC CANCER DRUGS, VERSUS REAL WORLD DATA ON PRESCRIBING ACTIVITY AND LEVELS OF SATISFACTION IN THE EU5Caldeira, R. / Franceschetti, A. et al. | 2018
- S70
-
PCN333 - REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER CLASSIFIED AS RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPYByrne, K. / Moon, R. / Chang, J. / Hubanova, P. / Doherty, J.P. / Cappelleri, J.C. et al. | 2018
- S72
-
PCN345 - HEALTH STATE UTILITIES IN METASTATIC NSCLC: A STUDY OF MULTIPLE IMMUNO-ONCOLOGY TRIALSHuang, M. / Chandwani, S. / Insinga, R. / Burke, T. / Pellissier, J. / Pickard, A.S. et al. | 2018
- S73
-
PCN350 - EVALUATION OF DISEASE-SPECIFIC SKIN SYMPTOM ITEMS ON SKINDEX-29 IN CUTANEOUS T-CELL LYMPHOMA PATIENTS TREATED WITH MOGAMULIZUMAB OR VORINOSTATHudgens, S. / Floden, L. / Leoni, M. / Nikonova, E. / Quaglino, P. et al. | 2018
- S74
-
PCN356 - HOW SHOULD WE VALIDATE UTILITY MAPPING ALGORITHMS BEFORE USE? AN EXAMPLE IN NON-SMALL CELL LUNG CANCERGregory, J. / Dyer, M. / Hoyle, C. / Mann, H. / Hatswell, A.J. et al. | 2018
- S75
-
PCN362 - UNDERSTANDING PATIENT AND CLINICIAN PERCEPTIONS OF CELL AND GENE THERAPY IN ONCOLOGY USING QUALITATIVE ANALYSES OF SOCIAL MEDIA DATAMerinopoulou, E. / Cooper, O. / Hareendran, A. / Booth, A. / Faulkner, E.C. / Spinner, D.S. / Bruno, A. / Arjunji, R. et al. | 2018
- S76
-
PCN368 - CONCORDANCE BETWEEN PATIENTS AND CLINICIANS' REPORTING OF SYMPTOMATIC ADVERSE EVENTS IN CANCER CLINICAL TRIALS: A SYSTEMATIC REVIEWSparano, F. / Aaronson, N. / Cottone, F. / Piciocchi, A. / La Sala, E. / Anota, A. / Deliu, N. / Kieffer, J.M. / Efficace, F. et al. | 2018
- S79
-
PCN383 - ESTIMATING THE HEALTH IMPACT OF INCREASING BREAST AND CERVICAL CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM AMONG LOW-INCOME WOMEN IN THE UNITED STATESEkwueme, D.U. / Pollack, L.M. / Hung, M. / Khushalani, J.S. / Miller, J.W. / Chang, S. et al. | 2018
- S82
-
PCP6 - HOW TO INTRODUCE MULTI-INDICATION BASED PRICING IN FINLAND?Karppinen, M.L. / Ihalmo, P. / Hjortsberg, C. et al. | 2018
- S83
-
PCP13 - IMPACT OF OUTCOME BASED ANNUITIES ON SMALL BIOTECH COMPANIESNevins, J.F. / Colasante, W. / Rahmati, D. et al. | 2018
- S84
-
PCP19 - AN UPDATED NICE POSITION ON THE EQ-5D-5L VALUATION SETCooper, S. / Bouvy, J. / Boysen, M. / Robertson, J. et al. | 2018
- S86
-
PCP34 - BIOSIMILARS: WHAT'S THE ISSUE?Mahi, L. / Barral, G. et al. | 2018
- S88
-
PCP48 - STABILITY OF RESULTS IN SIMULATION BASED HEALTH ECONOMIC MODELSGal, P. / Kovacs, V. et al. | 2018
- S90
-
PCP60 - EVOLVING STRATEGIES FOR GENERATING, SYNTHESIZING, AND VISUALIZING REAL WORLD EVIDENCE IN RARE DISEASESSzabo, S.M. / Johnston, K.M. et al. | 2018
- S91
-
PCP65 - KEY CONSIDERATIONS FOR THE COLLECTION OF PATIENT REPORTED OUTCOME (PRO) DATA IN REAL WORLD (RW) STUDIESRylands, A.J. / Boxell, E. / Bottomley, C.J. et al. | 2018
- S93
-
PCV7 - COMPARATIVE EFFECTIVENESS OF ORAL PROSTACYCLIN PATHWAY DRUGS ON HOSPITALIZATION AMONG PATIENTS WITH PULMONARY HYPERTENSION: A RETROSPECTIVE ADMINISTRATIVE CLAIMS STUDY IN A MANAGED CARE POPULATION IN THE USTsang, Y. / Drake, W. / Pruett, J. et al. | 2018
- S94
-
PCV12 - SHOULD KCENTRA BE ADDED FOR TREATMENT IN EMERGENCY WARFARIN REVERSAL?Oh, J. / Tsitarava, M. / Loh, F.E. et al. | 2018
- S96
-
PCV26 - LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALYFanelli, F. / Gazzi, L. / Heiman, F. / Peduto, I. / Pegoraro, V. et al. | 2018
- S97
-
PCV33 - THE RATE OF CARDIOVASCULAR EVENTS IN DIABETIC PATIENTS IN COLOMBIARomero, M. / Marino, C. / Cruz, A.M. / Rigueros, J. et al. | 2018
- S98
-
PCV38 - BUDGET IMPACT OF ALIROCUMAB IN THE MANAGEMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN ARGENTINAGiorgi, M.A. / Boissonnet, C.P. / Micone, P.V. / Gallo, M. / Stuart, P. / Giglio, N.D. et al. | 2018
- S99
-
PCV43 - BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ATORVASTATIN, PERINDOPRIL AND AMLODIPINE IN THE GREEK SETTINGStafylas, P. / Karaiskou, M. / Zouka, M. et al. | 2018
- S100
-
PCV49 - A REAL WORLD COST COMPARISON BETWEEN THOSE USING SALVIANOLATE INJECTION AND NOT AMONG CHINESE PATIENTS WITH CORONARY HEART DISEASE OR ANGINA PECTORIS: A RETROSPECTIVE DATABASE STUDYXu, Y. / Liu, H. / Gao, Y. / Xuan, J. et al. | 2018
- S102
-
PCV62 - THE 1-YEAR PRODUCTIVITY LOSS AND INDIRECT COSTS AFTER ACUTE CARDIOVASCULAR EVENTS IN POLANDDudek, D.Z. / Lamotte, M. / Sawicka, M. / Huczek, Z.J. / Depukat, R. / Rajtar-Salwa, R. / Krupiarz, M. / Duma, K. / Sidelnikov, E. et al. | 2018
- S103
-
PCV67 - STAR ANALYSIS AND FORECAST MODELLING TO ESTIMATE VALUE FOR MONEY OF ORAL ANTICOAGULANTSOrlowski, A. / Slater, R. / Ashton, R. / Glover, R. et al. | 2018
- S104
-
PCV74 - COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISKGarcía-Goñi, M. / Fácila, L. / Cinza, S. / Pinto, X. / Cortes, X. / Prades, M. / Aceituno, S. et al. | 2018
- S105
-
PCV80 - COST-EFFECTIVENESS OF NOACS IN PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN THE CZECH REPUBLICKolek, M. / Weber, J. / Karbusicka, M. / Vothova, P. / Mazan, P. / Duba, J. et al. | 2018
- S106
-
PCV85 - COST-EFFECTIVENESS OF BETRIXABAN COMPARED WITH ENOXAPARIN OR FONDAPARINUX FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALISED ACUTE MEDICALLY ILL PATIENTS IN THE UNITED KINGDOMLaskier, V. / Guy, H. / Fisher, M. / Neuman, W.R. / Bucior, I. / Deitelzweig, S.B. / Cohen, A. et al. | 2018
- S107
-
PCV91 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR ELECTIVE TOTAL KNEE REPLACEMENT SURGERY: A COST-UTILITY ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATIONDawoud, D. / Wonderling, D. / Lewis, S. / Glen, J. / Griffin, X. / Reed, M. / Rossiter, N. / Stansby, G. / Hunt, B.J. / Chahal, J.K. et al. | 2018
- S108
-
PCV96 - HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE: FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS)Annemans, L. / Azuri, J. / Al-Rasadi, K. / Al-Zakwani, I. / Daclin, V. / Mercier, F. / Danchin, N. et al. | 2018
- S109
-
PCV103 - MANAGEMENT OF ATHEROGENIC DYSLIPIDEMIA IN REAL CLINICAL PRACTICE WITHIN THE SPANISH HEALTH SYSTEM ACCORDING TO CURRENT TREATMENT GUIDELINES: DESPEGA STUDYAceituno, S. / Millan, J. / Rodriguez, P. / Rodríguez de Miguel, M. / Melogno Klinkas, M. / Orera - Peña, M.L. et al. | 2018
- S110
-
PCV108 - PRESCRIBING CHOICE AND THE COST OF ANTICOAGULATION IN ATRIAL FIBRILLATION: A REAL WORLD STUDY COMPARING HEALTHCARE EXPENDITURE WITH WARFARIN AND APIXABANSchinle, P. / Keogh-Bootland, S. / du Feu, J. / Durno, K. / How, W.J. / Hill, N. / Gordon, J. / Sugrue, D. / Beresford, L. / Lister, S. et al. | 2018
- S111
-
PCV114 - PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF NOVEL ORAL COAGULANTS IN A LARGE HEALTHCARE SERVICE PROVIDER IN ISRAELWeitzman, D. / Bourvine, L. / Tirosh, M. / Shalev, V. / Chodick, G. et al. | 2018
- S112
-
PCV120 - INDICATORS OF PRESCRIPTIVE APPROPRIATENESS AS A LEVER FOR PHARMACEUTICAL SUSTAINABILITY - THE CASE OF LOW MOLECULAR WEIGHT HEPARINSAndretta, M. / Degli Esposti, L. et al. | 2018
- S113
-
PCV127 - EFFECT OF LIPID TESTING INTERVAL ON CARDIOVASCULAR DISEASE AMONG NEWLY DIAGNOSED DYSLIPIDEMIA PATIENTSKo, A. / Choi, S. / Chang, J. / Park, S.M. et al. | 2018
- S114
-
PCV135 - NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS PRESCRIPTION MONITORING: HOW TO OPTIMIZE VIGILANCE IN STROKE PREVENTIONJacobs, M.S. / van Hulst, M. / Campmans, Z. / Tieleman, R.G. et al. | 2018
- S115
-
PCV145 - A SYSTEMATIC LITERATURE REVIEW (SLR) ON HEALTH STATE UTILITIES ASSOCIATED WITH ANGINA AND REVASCULARISATIONNatani, H. / Gogna, S. / Jindal, R. / Laires, P.A. / Cristino, J. et al. | 2018
- S116
-
PCV150 - HEALTH CARE RESOURCE USE AND QUALITY OF LIFE IN PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL: A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY)Afonso-Silva, M. / Laires, P.A. / Gonçalves, C. / Cary, M. / Guerreiro, J.P. / Romão, M. / Teixeira Rodrigues, A. et al. | 2018
- S117
-
PCV155 - EVALUATING THE IMPACT OF PHARMACIST INTERVENTION ON DISEASE KNOWLEDGE, ILLNESS PERCEPTIONS, AND BELIEF TOWARDS MEDICATIONS IN ACUTE CORONARY SYNDROME PATIENTS IN HONG KONGLee, V.W. / So, S.C. / Yeo, J. / Yan, B.P. et al. | 2018
- S119
-
PDB7 - THE EFFECT OF GLYCATED HEMOGLOBIN CONTROL ON DIABETIC FOOT COMPLICATIONSHammad, M.A. / Syed Sulaiman, S.A. / Sha'aban, A. / Mohamed Noor, D.A. et al. | 2018
- S120
-
PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONSBalijepalli, C. / Ayers, D. / Kandaswamy, P. / Ustyugova, A.V. / Pfarr, E. / Lund, S.S. / Druyts, E. et al. | 2018
- S122
-
PDB24 - BASELINE CHARACTERISTICS OF GERMAN DIABETES MELLITUS TYPE-2 PATIENTS WHO INITIATED INSULIN USAGE: A CLAIMS DATA ANALYSISGabler, M. / Picker, N. / Mueller, S. / Wilke, T. / Geier, S. / Försch, J. / Aberle, J. / Martin, S. / Riedl, M. et al. | 2018
- S123
-
PDB32 - SEX- AND SITE-SPECIFIC DIFFERENCES IN COLORECTAL CANCER RISK AMONG PEOPLE WITH TYPE 2 DIABETESOverbeek, J.A. / Kuiper, J.G. / van der Heijden, A.A. / Labots, M. / Haug, U. / Herings, R.M. / Nijpels, G. et al. | 2018
- S124
-
PDB40 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF TYPE 2 DIABETES &ENHANCEMENT PATIENT'S OUTCOMES AT COUNTRIES WITH HIGH INCIDENCE OF DIABETES EGYPT CASEAbotaleb, A. / Amin, M. et al. | 2018
- S125
-
PDB46 - CLINICAL AND ECONOMIC BURDEN OF TYPE 1 DIABETES IN REAL-LIFE SETTING IN SPAINSicras-Mainar, A. / Navarro-Artieda, R. et al. | 2018
- S126
-
PDB52 - ANNUAL COST OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TURKEYÖksüz, E. / Malhan, S. / Balbay, Y. / Bozkurt, E. / Ersoy, R. / Tetik, E. / Urganci, B. / Kamaci, E. / Cheynel, J. et al. | 2018
- S127
-
PDB58 - REIMBURSEMENT FOR TYPE 2 DIABETES MELLITUS PATIENTS HOSPITALIZED IN A MUNICIPAL HOSPITAL IN THE CZECH REPUBLICLoncak, V. / Bartak, M. / Rogalewicz, V. et al. | 2018
- S128
-
PDB64 - SHORT-TERM COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC IN JAPANESE PATIENTS WITH TYPE 2 DIABETESLanger, J. / Wolden, M.L. / Shimoda, S. / Sato, M. / Araki, E. et al. | 2018
- S129
-
PDB69 - COST-EFFECTIVENESS ANALYSIS OF ADDING PIOGLITAZONE TO INSULIN REGIMEN IN TYPE2 DIABETES IN IRANDavari, M. / Khorasani, E. / Savari Shojaei, R. / Akbari, Sari A / Saiyarsarai, P. et al. | 2018
- S130
-
PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLICRussel-Szymczyk, M. / Parekh, W. / Rychna, K. / Pöhlmann, J. / Hunt, B. et al. | 2018
- S131
-
PDB79 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIABogdanovic, M. / Fournier, M. / Vitezic, D. et al. | 2018
- S132
-
PDB84 - HETEROGENEITY OF TREATMENT EFFECT IN THE DIABETES PREVENTION PROGRAM: HIGH BASELINE RISK OF DEVELOPING DIABETES MAY PROVIDE A PLACE FOR METFORMIN IN DIABETES PREVENTION THAT USING OVERALL SAMPLE AVERAGE COSTS AND EFFECTS CONCEALSAlolayan, S. / Eguale, T. / Segal, A. / Doucette, J. / Rittenhouse, B. et al. | 2018
- S133
-
PDB89 - THE BURDEN OF PREGNANCY HYPERGLYCEMIA IN INDONESIAN WOMENFitria, N. / Utama, B. / Pradipta, I. / Schmidt, A. / van Asselt, A. / Postma, M.J. et al. | 2018
- S134
-
PDB95 - REAL WORLD EVIDENCE ON TYPE 2 DIABETES: IDENTIFICATION AND CHARACTERIZATION OF NON-INSULIN TREATED PATIENTS WHO FULFIL CONDITIONS FOR THAT TREATMENTAscenção, R. / Fiorentino, F. / Costa, J. / Gouveia, M. / Borges, M. et al. | 2018
- S135
-
PDB101 - THERAPY ADJUSTMENT IN ADULT T2DM PATIENTS WITH RENAL IMPAIRMENT TREATED WITH DPP-4 INHIBITORS IN THE UK: A RETROSPECTIVE COHORT STUDYSpanopoulos, D. / Poole, C. / Barrett, B. / Busse, M. / Roman, T. / Khunti, K. et al. | 2018
- S137
-
PDB114 - DRUG UTILIZATION STUDY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN AN ITALIAN REAL-WORLD SETTING: A RETROSPECTIVE STUDYDegli Esposti, L. / Perrone, V. / Saragoni, S. / Blini, V. / D'Avella, R. / Gasperini, G. / Lena, F. / Fanelli, F. / Gazzi, L. / Giorgino, F. et al. | 2018
- S138
-
PDB119 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH MEALTIME INSULIN CONCENTRATIONS AMONG PATIENTS WITH DIABETES IN ITALYMatza, L.S. / Osumili, B. / Stewart, K.D. / Perez, M. / Jordan, J. / Biricolti, G. / Romoli, E. / Losi, S. / Del Santo, S. / Spaepen, E. et al. | 2018
- S139
-
PDB125 - A DISCRETE CHOICE EXERCISE TO EVALUATE FACTORS DRIVING GROWTH HORMONE DEFICIENT (GHD) PATIENT PREFERENCES FOR INJECTION AND INJECTION DEVICE FEATURESMcNamara, M. / Westhead, H. / Gross, H. / Turner-Bowker, D.M. / Yaworsky, A. / Pleil, A. / Loftus, J.V. et al. | 2018
- S140
-
PDB132 - TYPE 2 DIABETES TREATMENT PATHS AND PATIENT OUTCOMES IN RESPONSE TO REIMBURSEMENT POLICY CHANGE IN FINLANDRuotsalainen, J. / Balcerzak, M. et al. | 2018
- S142
-
PGI8 - SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF LINACLOTIDE VERSUS OTHER ORAL CONSTIPATION TREATMENTS IN PATIENTS WITH CHRONIC CONSTIPATIONOkumura, H. / Tang, W. / Iwasaki, K. / Shoji, S. / Odaka, T. / Nakajima, A. et al. | 2018
- S143
-
PGI13 - REAL-LIFE BUDGET IMPACT OF DIRECT-ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS IN AN SPANISH PUBLIC HOSPITAL PHARMACYMargusino-Framiñán, L. / Cid-Silva, P. / Mena-de-Cea, A. / Vazquez-Rodriguez, P. / Rodriguez-Osorio, I. / Lopez-Calvo, S. / Pernas-Souto, B. / Martin-Herranz, I. / Castro-Iglesias, A. et al. | 2018
- S147
-
PGI39 - DARVADSTROCEL IN THE MANAGEMENT OF COMPLEX PERIANAL FISTULAS: THE ROLE OF PATIENT REGISTRY DATA COLLECTION TO SUPPORT PERFORMANCE-BASED RISK SHARING AGREEMENTSSchmetz, A. / Petrakis, I. / Khalid, J.M. / Minda, K. / Agboton, C. / Rawson, K. / Baumgart, D.C. et al. | 2018
- S148
-
PGI44 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) REPORT POSITIVE EXPERIENCE AFTER PARTICIPATING IN AN ONLINE QUANTITATIVE PREFERENCE SURVEYCook, N.S. / Balp, M. / Chatterjee, S. / Nagar, S. / Chirilov, A. / Weiss, O. / Schattenberg, J.M. / Schmid, A. / Hirschfield, G. / Kautz, A. et al. | 2018
- S149
-
PGI48 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) HAVE WORSE HEALTH RELATED QUALITY OF LIFE (HRQOL) THAN MATCHED CONTROLS: RESULTS FROM THE 2016 EU5 NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)Balp, M. / Krieger, N. / Przybysz, R. / Way, N. / Cai, J. / Zappe, D. / Mckenna, S.J. / Wall, G. / Janssens, N. / Tapper, E. et al. | 2018
- S151
-
PHP8 - THE ROLE OF GENERAL PRACTITIONERS IN TRAUMA CARE: VARIATION BY INJURY TYPE, REGION, PATIENT PROFILE, AND OVER TIMEHöglinger, M. / Knöfler, F. / Scholz, S. / Schaumann-von Stosch, R. / Eichler, K. et al. | 2018
- S152
-
PHP13 - USAGE OF DIETARY SUPPLEMENTS BY GYM VISITING ATHLETES – EFFECTS, AWARENESS AND CONSCIOUSNESSIpolyi, D. / Molnár, A. / Oláh, A. / Karácsony, I. / Pakai, A. / Brantmüller, É. / Boncz, I. / Breitenbach, Z. et al. | 2018
- S153
-
PHP19 - ANALYSIS OF ONE-DAY SURGERY INTERVENTIONS AMONG PATIENTS UNDER THE AGE OF 18 IN HUNGARYPónusz, R. / Boncz, I. / Németh, N. / Kovács, D. / Varga, V. / Molics, B. / Gresz, M. / Endrei, D. et al. | 2018
- S154
-
PHP25 - MENTAL HEALTH COMORBIDITIES AND ELEVATED RISK OF OPIOID USE IN ELDERLY BREAST CANCER SURVIVORS USING ADJUVANT ENDOCRINE TREATMENTSDesai, R.A. / Camacho, F. / Tan, X. / LeBaron, V. / Blackhall, L. / Balkrishnan, R. et al. | 2018
- S155
-
PHP31 - IMPACT OF EUROPEAN MEDICINES AGENCY (EMA) CLINICAL TRIAL TRANSPARENCY POLICIES ON HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS IN GERMANYJones, C. / Cocklin, S.L. et al. | 2018
- S156
-
PHP36 - EU5 AND PHARMACEUTICAL RESPONSES TO THE SPREAD OF CARBAPENEM-RESISTANT BACTERIA: A POLICY AND PIPELINE REVIEWCollings, H. / Palmer, T. / Tavella, F. et al. | 2018
- S157
-
PHP43 - EVIDENCE FOR HIGH RISK CLASS MEDICAL DEVICES VERSUS NEW DRUGS IN GERMANY: WHAT'S THE DIFFERENCE?Mueller, E. / Neeser, K. / Oelze, I. et al. | 2018
- S158
-
PHP48 - INTERNATIONAL REFERENCE PRICING OF PHARMACEUTICALS: APPLY LIBERALLY OR USE SPARINGLY?Lockwood, C. / Rodrigues, T. / Ando, G. et al. | 2018
- S159
-
PHP56 - EARLY ACCESS PROGRAMS: AN ANALYSIS SINCE THEIR ESTABLISHMENT IN ITALYD'Ausilio, A. / Seyed Khoei, N. / Lanati, E.P. et al. | 2018
- S160
-
PHP62 - HOME BREWED AUTOLOGOUS THERAPIES: CAN BIOPHARMA WIN THE WAR WITH DOMESTIC AUTOLOGOUS CELL & GENE THERAPY MANUFACTURERS?Khurana, S. / Kumar, A. / Sotou, D.S. et al. | 2018
- S161
-
PHP67 - CURRENT INITIATIVES & FUTURE OF E-HEALTH FUNDING PATHSKloc, K. / Lach, S. / Dusza, M. / Rémuzat, C. / Sediri, Y. / Palencia, R. / Abshagen, D. / Toumi, M. et al. | 2018
- S162
-
PHP72 - A NEW FRENCH FINANCIAL INCENTIVE TO BOOST INSULIN AND ETANERCEPT BIOSIMILARS PRESCRIBING: SIMULATION OF ECONOMIC IMPACTS FOR THE PUBLIC HOSPITALS OF PARISAdé, A. / Degrassat-Théas, A. / Bocquet, F. / Parent de Curzon, O. / Paubel, P. et al. | 2018
- S163
-
PHP78 - PRICING AND REIMBURSEMENT REFORMS IN SPAIN – A SYSTEMATIC ANALYSIS OF NATIONAL PRICING DECISIONS BY THE CIPMMacaulay, R. / Fernandez Dacosta, R. et al. | 2018
- S165
-
PHP93 - THE IMPACT OF SUPPLY CHAIN MARGINS AND VAT ON THE PRICES OF MEDICINES IN BULGARIA AND GREECECherneva, D. / Benisheva, T. et al. | 2018
- S166
-
PHP99 - OVER-THE-COUNTER MEDICINES USE AND ITS ASSOCIATION WITH RISK PERCEPTION AND SAFETY AMONG WOMEN VISITING COMMUNITY PHARMACIES IN MALAYSIAMittal, P. / Lai, K.Y. / Verma, R.K. / Hasan, S.S. et al. | 2018
- S167
-
PHP105 - A POPULATION-BASED DATA ANALYSIS OF DRUG PRESCRIPTION AND PATTERNS OF USE OF ANTIBIOTIC IN SOUTHERN ITALY POPULATIONMoreno Juste, A. / Guarino, I. / Russo, V. / Menditto, E. et al. | 2018
- S168
-
PHP110 - SUBSTANTIAL HEALTH GAINS FROM HEATH-SYSTEM-WIDE PATIENT BLOOD MANAGEMENT IMPLEMENTATION: ANALYTICS FOR EUROPEVandewalle, B. / Félix, J. / Ferreira, C. et al. | 2018
- S170
-
PHP121 - DISCRIMINATION IN ACCESS TO SCHEDULED SURGERY IN THE PORTUGUESE NHS: A SURVIVAL MODEL ANALYSISCima, J. / Almeida, A.S. et al. | 2018
- S171
-
PHP128 - 3F - FORMULA FOR FUNDING: RETHINKING THE PORTUGUESE HOSPITAL FUNDING SYSTEMLourenço, A. / Ventura, C. / Andrade, S. / Sousa, J. / Valadas, F. et al. | 2018
- S173
-
PHP139 - G-BA CONDITIONAL APPROVALS IN THE AMNOG PROCEDURE: IMPACT ON HTA OUTCOMES AND PRICEDehnen, J. / Petry, D. / Kruse, F. / Bercher, J. et al. | 2018
- S174
-
PHP144 - IMPACT OF A CREATIVE QUALITY IMPROVEMENT STRATEGY TO REDUCE PATIENT WAIT TIMES BETWEEN PRIMARY AND SPECIALITY CARE IN A TERTIARY, UNIVERSITY PUBLIC HOSPITAL IN PORTUGALCorreia, S. / Yantsides, C. / Amorim, A.P. / Monteiro, J.L. / Costa, L. / Gonçalves, A.M. / Azevedo, A. / Paiva, J.A. et al. | 2018
- S175
-
PHP151 - THE PERCEPTION OF THE PUBLIC ABOUT DISABILITY AND THE MEDICAL AND SOCIAL MODEL OF DISABILITY: A LITERATURE REVIEWFatoye, C. / Betts, A. / Odeyemi, A. / Fatoye, F. / Odeyemi, I. et al. | 2018
- S176
-
PHP156 - A SCENARIO ANALYSIS OF THE IMPACT OF TREATMENT SETTING ON HEALTH CARE COST AND TREATMENT OUTCOMESLewis, M. / Tavella, F. / Okhuoya, P. et al. | 2018
- S178
-
PHP167 - COUNTRY-LEVEL COST-EFFECTIVENESS THRESHOLD: INITIAL ESTIMATES IN REPUBLIC OF BELARUSKozhanova, I. / Sachek, M. et al. | 2018
- S180
-
PHP182 - EXTERNAL REFERENCE PRICING: CONSEQUENCES OF FRENCH PRICE DECREASES ON INTERNATIONAL TURNOVERLe Pen, C. / Sclison, S. / Ravonimbola, H. / Paolantonacci, J. / Baseilhac, E. / Savart, P. / Dorizon, D. / Vigneron, A. et al. | 2018
- S181
-
PHP188 - EVOLVING INDICATIONS – AN ANALYSIS OF INDICATION FIELDS OVER TIME BASED ON GERMAN PRESCRIBING INFORMATIONRavindra, S. / Boehler, Y. et al. | 2018
- S182
-
PHP193 - THE USE OF MEDTECH INNOVATION BRIEFINGS (MIBS) TO ENCOURAGE IMPLEMENTATION OF INNOVATIVE TECHNOLOGIES: A REVIEW OF PUBLISHED BRIEFINGS FROM 2014-2018Glen, F. / Pulfer, A. et al. | 2018
- S184
-
PHP206 - TUMOUR-AGNOSTIC AGENTS: ARE THEY FIT FOR REIMBURSEMENT?Khogeer, B. / Anjarwalla, N. / Doolub, N. / Grosvenor, A. et al. | 2018
- S185
-
PHP211 - ESTIMATION OF PHARMACEUTICAL CARE SERVICES IN UKRAINE: ISSUES AND WAYS FOR IMPROVEMENTDobrova, V. / Zupanets, I. / Shilkina, O. / Lishchyshyna, O. et al. | 2018
- S186
-
PHP217 - TIME TO MARKET AND PRICE COMPARISON FOR BIOSIMILAR DRUGS IN EU5López, N. / Prada, M. / Berard, I. / Schleich, W. / Melson, C. et al. | 2018
- S187
-
PHP222 - IDENTIFYING THE KEY DRIVERS AFFECTING THE REIMBURSEMENT OF THERAPEUTIC VACCINES IN EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERSKumar Singh, K. / Clapton, G.S. / Narjal, M. / Yadav, V. / Shah, C.S. et al. | 2018
- S189
-
PHP233 - DIVERGENCE IN UK HTA RECOMMENDATIONS: NOT ALWAYS A NICE OUTCOMEGriffiths, E.A. et al. | 2018
- S190
-
PHP238 - CARER DISUTILITY: IS IT ACCURATELY CAPTURED IN NICE APPRAISALS?Ferizovic, N. / Marshall, J.D. et al. | 2018
- S191
-
PHP243 - DO DISEASE SEVERITY AND/OR QUALITY OF CLINICAL DATA INFLUENCE PRICING POLICY IN FRANCE? AN ANALYSIS ON ORPHAN DRUGS AND BLOOD CANCERS TREATMENTSVandewalle, C. / Charoy, M. / Heurtebis, J. / Desplanches, L. / Gauthier, M. / de Sauvebeuf, C. et al. | 2018
- S192
-
PHP252 - IS FACTOR ANALYSIS AS CREDIBLE AS OTHER TESTS OF DIFFERENCE AND ASSOCIATION FOR EVALUATING THE VALIDITY OF QUALITY OF LIFE MEASURES? ASSESSING THE CONVERGENT AND DISCRIMINANT VALIDITY OF THE WOMEN'S HEALTH QUESTIONNAIRE AGAINST THE EQ-5D-5L AND SF-6DKaambwa, B. / Ratcliffe, J. et al. | 2018
- S193
-
PHP258 - DEVELOPMENT OF A REAL WORLD EVIDENCE STUDY DESIGN TOOLXia, A. / Schaefer, C. / Szende, A. / Jahn, E. / Dunlop, W. et al. | 2018
- S194
-
PHP265 - LANDSCAPE ASSESSMENT OF A MENA HEALTHCARE DATABASE FOR USE IN HEALTH ECONOMICS MODELINGMaskineh, C. / Becker, R.V. / Kosremelli Asmar, M. / Bekhazi, H. / Sleilaty, G. et al. | 2018
- S195
-
PHP270 - POPULARITY OF NURSING PROFESSION AMONGST STUDENTS WHO ARE BEFORE THE CAREER CHOICEFerenczy, M. / Dudás, M. / Pakai, A. / Karácsony, I. / Boncz, I. / Rozmann, N. / Komlósi, K. / Oláh, A. et al. | 2018
- S197
-
PHP281 - THE METHODOLOGICAL DIFFERENCES OF EUROPEAN JOINT ASSESSMENT AND GERMAN HTA: AN EMPIRICAL APPROACHPanni, T. / Thiele, A. / Carls, A. / Wallstab, A. / Eberle, K. / Schleibner, S. et al. | 2018
- S198
-
PHP286 - RESPONSES OF ISPOR MEMBERS TO THE RECOMMENDATIONS OF THE SPECIAL TASK FORCE ON US VALUE ASSESSMENT FRAMEWORKSOyeye, O. / Johnson, K.I. et al. | 2018
- S199
-
PHP291 - SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS: EXPERIENCES OF THREE PHARMACEUTICAL JOINT RAPID RELATIVE EFFECTIVENESS ASSESSMENTSWillemsen, A. / Estevão, S. / Dupree, R. et al. | 2018
- S200
-
PHP296 - MANAGED ACCESS AGREEMENTS (MAAS) AND CONTINUING DATA COLLECTION AFTER PROVISIONAL POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)Wordsworth, J. / Cork, D. / Curry, A. / Ralston, S. et al. | 2018
- S202
-
PHP307 - REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPEHanna, E. / Marre, C. / Toumi, M. et al. | 2018
- S203
-
PHP313 - ANALYSIS OF THE ANALYTICAL AND METHODOLOGICAL FRAMEWORK OF THE HEALTH ECONOMIC EVALUATION ASSESSMENTS DELIVERED IN FRANCECabout, E. / Launois, R. et al. | 2018
- S204
-
PHP319 - MANDATORY JOINT CLINICAL ASSESSMENT – WHAT IS THE ADDITIONAL INSIGHT FROM EU-NETHTA VS. EMA?Ecker, T. et al. | 2018
- S207
-
PHP337 - OFF-LABEL PRESCRIPTION OF DRUGS COMPARED TO PRESCRIPTION AFTER LABEL EXTENSION IN CHILDREN FOR GERMANYGohlke, A. / Kostev, K. / Kuschel, A. et al. | 2018
- S208
-
PHP342 - HOW TO MAXIMIZE THE EX-FACTORY PRICE IN PORTUGAL, WITH SIMULTANEOUS BENEFITS FOR PATIENTS AND PAYERS – AN INDUSTRY PERSPECTIVEHenriques, J. / Amorim, A. et al. | 2018
- S209
-
PHP348 - REGENERATIVE MEDICINE ADVANCED THERAPY: A BUDGET IMPACT ANALYSISHanna, E. / Marre, C. / Toumi, M. et al. | 2018
- S210
-
PHP353 - ROMANIAN EXPERIENCE WITH MANAGED ENTRY AGREEMENTS FOR DRUGSRadu, P. / Stoica, I. / Udroiu, P. et al. | 2018
- S211
-
PHP359 - IMPACT OF EXPEDITED MARKETING AUTHORISATION ON PRICING AND REIMBURSEMENT OUTCOMES FOR DRUGS IN THE US AND EU-5Izmirlieva, M.A. / Reinaud, F. / Ando, G. et al. | 2018
- S212
-
PHP365 - TRENDS AND CHARACTERISTICS OF MANAGED ACCESS AGREEMENTS APPROVED BY NICEMarsh, S.E. et al. | 2018
- S214
-
PIH7 - LONG-ACTING RECOMBINANT FSH (CORIFOLLITROPIN ALFA) VERSUS RECOMBINANT FSH AS ASSISTED REPRODUCTION TECHNIQUES IN THE MANAGEMENT OF INFERTILITY: A SYSTEMATIC REVIEW AND META-ANALYSISTaheri, S. / Varmaghani, M. / Heidari, E. / Yousefi, N. / Peiravian, F. et al. | 2018
- S216
-
PIH24 - MODELLED EFFECTS OF A PEDIATRIC TRIPLE-CHAMBER-BAG (3CB) SYSTEM ON PAYER COSTS AND CLINICAL OUTCOMES IN PRE-TERM NEONATES ACROSS FRANCE, GERMANY AND ITALYKriz, A. / Migliore, A. / Wright, A. / Piaggio, T. et al. | 2018
- S223
-
PIN18 - ESTIMATING THE BUDGET AND CLINICAL IMPACT OF INTRODUCING ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOMWeidlich, D. / Hicks, M.D. / Floros, L. / Patel, J. / Charbonneau, C. / Sung, A.H. et al. | 2018
- S224
-
PIN23 - CLINICAL AND ECONOMIC BURDEN OF INVASIVE MENINGOCOCCAL DISEASE IN FRANCEFievez, S. / Tin Tin Htar, M. / Goguillot, M. / Bénard, S. / Huang, L. et al. | 2018
- S225
-
PIN31 - ECONOMIC EVALUATION OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE ON CMV-SEROPOSITIVE RECEPTORS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT IN THE PORTUGUESE SETTINGFerreira, J. / Pereira, R. / Schelfhout, J. / Jiang, Y. et al. | 2018
-
PIN24 - ESTIMATION OF HOSPITAL COST SAVINGS ASSOCIATED WITH HYPOTENSION REDUCTION IN SEPTIC INTENSIVE CARE UNIT PATIENTS IN US HOSPITALSKeuffel, E. / Gunnarsson, C. / Stevens, M. / Davis, T. / Maheshwari, K. et al. | 2018
-
PCV161 - FOCUS ON LIFE QUALITY IN RECONSTRUCTION VASCULAR SURGERYVáradyné Horváth, Á / Agócs, G. / Pakai, A. / Szabó, L. / Szunomár, S. / Szebeni-Kovács, G. / Boncz, I. / Oláh, A. et al. | 2018
-
PIN11 - HPV9-RELATED DISEASES: THE ECONOMIC BURDEN ON THE SOCIAL SECURITY SYSTEM IN ITALYNardone, C. / Russo, S. / Marcellusi, A. / Migliorini, R. / Trabucco Aurilio, M. / Mennini, F.S. et al. | 2018
-
PIN16 - BUDGET IMPACT ANALYSIS OF INTRODUCING A READY-TO-USE, FULLY-LIQUID, PAEDIATRIC, HEXAVALENT VACCINE FOR CHILDHOOD IMMUNISATION IN THE UNITED KINGDOMMathijssen, D. / Clark-Wright, J. / Wolfson, L.J. / Lu, X. / Heisen, M. / Klijn, S. / Carroll, S. / Alemayehu, B. et al. | 2018
-
PIN17 - BUDGET IMPACT ANALYSIS OF LIPOSOMAL AMPHOTERICIN B VERSUS AMPHOTERICIN B LIPID COMPLEX FOR THE TREATMENT OF INVASIVE FUNGAL INFECTIONS IN A TERTIARY HOSPITAL IN THE KINGDOM OF SAUDI ARABIAAlJedai, A. / AlRaddadi, B. / Vemer, P. / Awad, N. / Safwat, M. / Mansour, E. / Hanna, E. et al. | 2018
-
PIN2 - IMPACT OF ADHERENCE TO HEDIS MEASURES ON THE QUALITY OF CARE FOR PEDIATRIC PATIENTS WITH PHARYNGITIS: EVIDENCE FROM A LARGE HEALTH PLANSangha, K. / Steinberg, I. / McCombs, J. et al. | 2018
-
PHP209 - FUNDING OF CLINICAL TRIALS IN UNIVERSITY HOSPITAL ENVIRONMENTZavadil, M. / Al Jamal, E.S. / Valtrová, V. et al. | 2018
-
PHP185 - BRAZIL'S ECONOMIC SITUATION AND THE EVOLUTION OF THE PRIVATE HEALTHCARE SYSTEMChabrol Haas, L. / Ranieri, A.S. / Bottino, M.C. / Clemente, V. et al. | 2018
-
PHP169 - MCDA EVIDEM REFERENCE VALUE FRAMEWORK FOR DRUG EVALUATION AND DECISION MAKING IN SPAINBadia, X. / Gil, A. / Shepherd, J. et al. | 2018
-
PHP163 - THE FRENCH HEALTH ECONOMIC RESEARCH PROGRAM(PRME): AN OVERVIEW SINCE ITS CREATION IN 2013Corthier, M. / Maillant, L. / Mézerette, B. et al. | 2018
-
PHP119 - DISRUPTION IN PATIENT ACCESS TO INNOVATIVE THERAPY IN FRANCE AFTER INTERRUPTION OF NOMINATIVE TEMPORARY AUTHORISATION FOR USEWeber, A. / Marre, C. / Leveque, D. / Toumi, M. et al. | 2018
-
PHP103 - OUT-OF-POCKET EXPENDITURE FOR PRESCRIBED AND OVER-THE-COUNTER MEDICATIONS IN GREECENaoum, P. / Kyriopoulos, I. / Karampli, E. / Athanasakis, K. / Kyriopoulos, J. et al. | 2018
-
PHP88 - CLINICAL ADDED VALUE ASSESSMENT OF ANTI-INFECTIVES FOR SYSTEMIC USE BY FRENCH TRANSPARENCY COMMITTEE IS CORRELATED WITH THE PUBLIC HEALTH BENEFITGauthier, M. / Desplanches, L. / Heurtebis, J. / Vandewalle, C. / Charoy, M. / de Sauvebeuf, C. et al. | 2018
-
PHP51 - UTILIZTION OF MONOCLONAL ANTIBODY IN CHINA: A STUDY FROM NATOINAL MARKET ACCESS VIEWLai, Y. / Bie, R. / Suo, S. / Shi, H. / Chen, S. / Ung, C.O. / Hu, H. et al. | 2018
-
PHP28 - EXPLANATIONS FOR THE DIFFERENCES BETWEEN EFFECTS ON ADHERENCE OF VALUE-BASED HEALTH INSURANCE DESIGNS: A SYSTEMATIC REVIEW AND META-ANALYSISKrack, G. et al. | 2018
-
PGI46 - PSYCHOMETRIC EVALUATION OF THE DIARY FOR IRRITABLE BOWEL SYNDROME SYMPTOMS-CONSTIPATION (DIBSS-C)Fehnel, S. / Ervin, C. / McLeod, L. / Carson, R.T. / Reasner, D. / Hanlon, J. / Eremenco, S. / Coons, S.J. et al. | 2018
-
PHP10 - PATIENTS' INVOLVEMENT IN THE DEVELOPMENT OF TARGET PRODUCT PROFILE, PRODUCT DEVELOPMENT PLAN AND THE DESIGN OF CLINICAL TRIALSFatoye, C. / Betts, A. / Odeyemi, A. / Fatoye, F. / Odeyemi, I. et al. | 2018
-
PDB105 - INCREASED BURDEN OF MULTIMORBIDITY AMONGST DIABETES PATIENTS: A MULTINATIONAL SURVEYHiggins, V. / Sullivan, E. / Harrison, O. / Piercy, J. et al. | 2018
-
PDB100 - STUDY ON AWARENESS REGARDING NEWER TRENDS IN DIABETES MEDICATION MANAGEMENTKarnik, S. / Janodia, M. / Jadhav, S. / Parolia, S. et al. | 2018
-
PHP346 - THE EVOLUTION FROM INTEREST TO EXECUTION: AN ANALYSIS OF RECENT TRENDS IN OUTCOMES BASED CONTRACTING ACROSS THE US AND EULehmann, H. / Erickson, G. / Eslami, N. / Garfield, S. / Richardson, S. et al. | 2018
-
PHP333 - ADDRESSING THE CHALLENGE OF CHRONICITY IN A REGION OF SPAIN. TAKING STEPS TOWARDS A PARTNERSHIP BETWEEN THE HEALTH CARE ADMINISTRATION AND THE PHARMACEUTICAL INDUSTRYSánchez-Agustino, M. et al. | 2018
-
PHP331 - IS IT ENOUGH TO HAVE IT IN THE VACCINATION PROGRAMME? AN EMPIRICAL ANALYSIS OF THE FACTORS THAT AFFECT INFLUENZA VACCINATION UPTAKE IN ADULTS IN GREECEAthanasakis, K. / Kyriopoulos, I. / Kyriopoulos, J. et al. | 2018
-
PHP288 - INCLUSION OF QUANTITATIVE PREFERENCE DATA TO UNDERSTAND TREATMENT PREFERENCE IN HTA APPLICATIONS IN THE UKLewis, H.B. / Latibeaudiere, D. / Janssen, E. / Justo, N. et al. | 2018
-
PHP253 - WAYS OF IMPROVING PHARMACEUTICAL ASSISTANCE IN UKRAINE THROUGH THE DEVELOPMENT OF PHARMACEUTIST PROTOCOLSLishchyshyna, O. / Shilkina, O. et al. | 2018
-
PHP212 - A DECADE OF PUBLIC-PRIVATE PARTNERSHIPS (PDPS) IN BRAZIL: AN EXPLORATORY ANALYSIS OF PROGRESS AND CHALLENGESMusleh, E. / Saggia, M.G. et al. | 2018
-
PDB91 - EXPLAINING THE DISPARITIES OF MARKET ACCESS FOR GLIFLOZINS IN FRANCE, SPAIN, GERMANY AND THE UNITED-KINGDOMBodaghi, C. / Benque, E. / Troubat, A. et al. | 2018
-
PDB80 - RE-ANALYSIS OF THE DIABETES PREVENTION PROGRAM 3 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) USING IDENTICAL DATA BUT PROPER METHODS QUESTIONS ITS CONCLUSIONSAlolayan, S. / Eguale, T. / Segal, A. / Doucette, J. / Rittenhouse, B. et al. | 2018
-
PDB70 - ECONOMIC EVALUATION OF THE USE OF RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR (HEBERPROT-P®) AS AN ADJUVANT OF CONVENTIONAL THERAPY FOR THE TREATMENT OF DIABETIC FOOT ULCERMuzio, V. / Gonzalez, O. / Garcia, D. / Flores, B. / Alcantara, J.L. / Figueroa, A. / Lemus, F. et al. | 2018
-
PDB73 - INDIRECT COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN COMPARED TO CANAGLIFLOZIN FOR PATIENTS WITH T2DM AND CARDIOVASCULAR DISEASE IN THE SPANISH NATIONAL HEALTH SERVICECarrasco Perez, M. / Male, N. / Serra Burriel, M. / Pfarr, E. / Kansal, A. et al. | 2018
-
PDB43 - THE COSTS AND RESULTS OF INCRETINS'AND SGLT-2I DIABETES THERAPY IN BULGARIAMitkova, Z. / Valov, V. / Mitov, K. / Manova, M. / Savova, A. / Kamusheva, M. / Tcharaktchiev, D. / Angelov, Z. / Angelova, G. / Petrova, G. et al. | 2018
-
PDB45 - COSTS OF PREVENTION, MONITORING AND TREATMENT OF IODINE DEFICIENCY DISORDERS IN GERMANYSchaffner, M. / Rochau, U. / Mühlberger, N. / Conrads-Frank, A. / Sroczynski, G. / Vukićević, D. / Koukkou, E. / Voelzke, H. / Thuesen, B.H. / Qerimi, V. et al. | 2018
-
PDB50 - COST OF HYPOGLYCAEMIA IN BOSNIA AND HERZEGOVINAČatić, T. / Jusufović, R. et al. | 2018
-
PDB13 - SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF SGLT-2 INHIBITORS AND METFORMIN AS ADD-ON TO INSULIN FOR THE TREATMENT OF TYPE 1 DIABETESLangford, B. / Evans, M. / Haskins-Coulter, T. / O'Connor, M. / Eddowes, L.A. / Edmonds, C. / Tank, A. et al. | 2018
-
PCV115 - QUALITY OF INR CONTROL AND SWITCHING TO DOAC BETWEEN WOMEN AND MEN WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN K ANTAGONISTS IN SPAIN. A POPULATION-BASED, REAL-WORLD STUDY.Garcia-Sempere, A. / Hurtado, I. / Bejarano, D. / Rodriguez-Bernal, C. / Santaana, Y. / Peiro, S. / Sanfelix, G. et al. | 2018
-
PDB9 - ASSOCIATION BETWEEN CLASS OF ANTIDIABETIC DRUGS AND INCIDENCE OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELITUS: A PROPORTIONAL HAZARD ANALYSIS USING DEEP LEARNING FOR RISK ADJUSTMENTYamada, T. / I.T.O., K. / Takeshima, T. / Iwasaki, K. et al. | 2018
-
PCV147 - A TARGETED LITERATURE REVIEW OF HEALTH STATE UTILITIES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)Dimri, S. / Agrawal, R. / Cristino, J. / Laires, P.A. et al. | 2018
-
PCV84 - COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION SPANISH PATIENTSde Andrés-Nogales, F. / Oyagüez, I. / Suarez, C. / Lopez-Sendon, J.L. / Gonzalez-Juanatey, J.R. / Suarez, J. / Polanco, C. et al. | 2018
-
PCV68 - POTENTIAL SAVINGS IN HIGHEST PRESCRIBING REGIONS FOR DIRECT-ACTING ORAL ANTICOAGULANTS IN ENGLANDOrlowski, A. / Slater, R. / Smith, W. / Ashton, R. / Dewar, T. et al. | 2018
-
PCN238 - TIME TO APPROVAL USING ACCELERATED MARKETING AUTHORIZATION PATHWAYS: A STUDY OF FIVE DEVELOPED COUNTRIESBerdunov, V. / Mesana, L. / Hancock-Howard, R. / Syed, I.A. et al. | 2018
-
PCV71 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF SYMPTOMATIC CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGALAlarcão, J. / Ascenção, R. / Costa, J. / Gouveia, M. / Borges, M. et al. | 2018
-
PCN253 - DID THE EUROPEAN FINANCIAL CRISIS HAVE AN IMPACT ON ECONOMIC DECISION-MAKING IN HEALTH TECHNOLOGY ASSESSMENTS?Gizaw, N. / Farinella, M. / Inumerable, R.V. / Rubinstein, J. / Ho, Y. et al. | 2018
-
PCN251 - DESCRIPTIVE ANALYSIS OF THE USE OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKAEMIA IN EUROPE, A REAL-WORLD PERSPECTIVEMartinez de Pinillos, A. / Nasuti, P. / Anger, C. / Ricote, I. et al. | 2018
-
PCN203 - HEALTHCARE RESOURCE USE IN PATIENTS WITH END-STAGE ADVANCED CUTANEOUS T-CELL LYMPHOMA (CTCL): RESULTS OF SEVEN SEMI-STRUCTURED INTERVIEWS ACROSS LEADING UK CENTRESPodkonjak, T. / Ovcinnikova, O. / Cranmer, H. / Benson, E.M. / Hatswell, A.J. / Field, F. et al. | 2018
-
PCN158 - THE ADDED VALUE OF PERSONALIZED FOLLOW-UP FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTSBakker, L.J. / Redekop, K. / Aarts, J.E. et al. | 2018
-
PCN205 - OUTCOMES OF DECISION AIDS USED IN ONCOLOGY: A SYSTEMATIC REVIEWCovvey, J.R. / Kamal, K.M. / Dhumal, T. / Mehta, Z. / Zacker, C. et al. | 2018
-
PCN164 - THE APPLICATION OF A RESPONSE-BASED MODELLING APPROACH WITH A LANDMARK POINT: IMPLICATIONS AND CHALLENGES FOR THE ECONOMIC EVALUATION OF NIVOLUMAB FOR ADVANCED/METASTATIC UROTHELIAL CARCINOMA IN THE UKGreen, W. / Shore, J. / Schoenherr, N. / Wickstead, R.M. / Tyas, D. et al. | 2018
-
PCN165 - COST-EFFECTIVENESS OF SORAFENIB FOR METASTATIC RENAL CELL CARCINOMA: A SYSTEMATIC REVIEWTaheri, S. / Motevalli, M.H. / Peiravian, F. / Yousefi, N. et al. | 2018
-
PCN126 - DIRECT COST STUDY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) FOR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM THE FRENCH HOSPITAL PERSPECTIVEDuteil, E. / Lafon, T. / Blein, C. / Affinito, S. / Duco, J. / Oprea, C. / Vieira dos santos, C. et al. | 2018
-
PCN112 - BURDEN AND COSTS OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN PORTUGALPaquete, A.T. / Silva Miguel, L. / Costa, J. / Alarcão, J. / Fiorentino, F. / Guerreiro, R. / Borges, M. et al. | 2018
-
PCN85 - SAVING HEALTHCARE AND SOCIETAL COSTS BY CHANGING THE ROUTE OF ADMINISTRATION OF ONCOLOGY DRUGSFranken, M.G. / Kanters, T.A. / Coenen, J.L. / de Jong, P. / Koene, H.R. / Lugtenburg, P.J. / Jager, A. / Uyl-de Groot, C.A. et al. | 2018
-
PCN56 - TREATMENT EFFECT MODIFICATION (EM) OF ANTICANCER THERAPIES IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A SYSTEMATIC ASSESSMENT OF TRIAL DATAWang, S. / Varol, N. / Waser, N. / Thompson, J.C. / Penrod, J.R. / Yuan, Y. / Korytowsky, B. / Hertel, N. / Goring, S.M. et al. | 2018
-
PCN91 - PHARMACOECONOMIC EVALUATION OF ENZALUTAMIDE FOR THE TREATMENT OF POST-CHEMOTHERAPY PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN RUSSIAAvxentyev, N.A. / Derkach, E.V. / Makarov, A.S. et al. | 2018
-
PCN22 - MARKETING AUTHORISATION PRACTICE OF THE EUROPEAN MEDICINES AGENCY (EMA) IN ONCOLOGICAL INDICATIONSKordecka, A. / Walkiewicz-Żarek, E. / Łapa, J. / Sadowska, E. / Kordecki, M. et al. | 2018
-
PCN189 - ANALYSIS COST / UTILITY OF THE THERAPEUTIC THERAPY TREATMENT OF LUNG CANCER IN A UNIVERSITY HOSPITAL OF SPAINReyes-Santias, F. / Cordova-Arevalo, O. et al. | 2018
-
PCN18 - TREATMENT OF POST-MENOPAUSAL ADVANCED BREAST CANCER: NETWORK META-ANALYSIS USING SECOND-ORDER FRACTIONAL POLYNOMIALS MODELSHarvey, R.C. et al. | 2018
-
PCN4 - EFFECTIVENESS AND SAFETY OF PEMBROLIZUMAB IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCERMurteira, R. / Ramos, C. / Cardoso Borges, F. / Ferreira, M.M. / Miranda, A. / Alves da Costa, F. et al. | 2018
-
PCN9 - BRAIN TUMOR RESECTION SURGERY IN PEDIATRIC PATIENTS; RETROSPECTIVE EPIDEMIOLOGICAL STUDY USING JAPANESE ADMINISTRATIVE DATABASEShinjo, D. / Matsumoto, K. / Terashima, K. / Takimoto, T. / Noguchi, T. / Fushimi, K. et al. | 2018
-
PCN1 - REAL-WORLD EFFECTIVENESS AND TOLERABILITY OF SMALL-CELL LUNG CANCER (SCLC) TREATMENTS: A SYSTEMATIC LITERATURE REVIEW (SLR)Povsic, M. / Enstone, A. / Wyn, R. / Kornalska, K. / Penrod, J.R. / Yuan, Y. et al. | 2018
-
ND1 - AMBULATORY FUNCTION IN DUCHENNE MUSCULAR DYSTROPHY (DMD): THE CHARACTERISTIC TRAJECTORY AND VARIATION ACROSS INDIVIDUALSSignorovitch, J. / Muntoni, F. / Sajeev, G. / Yao, Z. / Ward, S.J. / Abrams, K.R. et al. | 2018
-
PCN6 - SYSTEMATIC LITERATURE REVIEW OF EFFICACY & SAFETY DATA FOR THE TREATMENT OF PREVIOUSLY UNTREATED, ADVANCED OR METASTATIC RENAL CELL CARCINOMABregman, C. / Supiot, R. / Pacou, M. / Doan, J. / Dale, P. / Malcolm, B. et al. | 2018
-
PCN15 - INVESTIGATION OF THE ASSOCIATION BETWEEN INCIDENT METFORMIN EXPOSURE AND NON-SMALL CELL LUNG CANCER DIAGNOSIS AMONG DIABETIC PATIENTSRuban, C. / Blanchette, C.M. / Howden, R. / Kowalkowski, M. / Marino, J. / Saunders, W.B. et al. | 2018
-
PCN147 - COST-EFFECTIVENESS SIMULATION AND ANALYSIS OF COLORECTAL CANCER SCREENING IN SHANGHAI POPULATION, CHINA: COMPARISON BETWEEN URBAN AND RURAL RESIDENTSDou, G. / Li, X. / Ying, X. et al. | 2018
-
PCN12 - COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN WESTERN EUROPEDaSilva, C. / Karki, C. / Wriede, V. et al. | 2018
-
PCN3 - REAL WORLD EVIDENCE OF METASTATIC BREAST CANCER TREATMENT: A COMPARISON OF ADVERSE EFFECTS BETWEEN PALBOCICLIB TREATMENT AND ENDOCRINE THERAPYKuranz, S. et al. | 2018
-
HT5 - FINDINGS FROM THE FIRST FIVE YEARS OF THE UK NICE HST PROGRAMCockerill, K. / Gaebler, J.A. et al. | 2018
-
MD3 - FROM DRUG-DELIVERY DEVICE TO DISEASE MANAGEMENT TOOL: A STUDY OF PATIENT PREFERENCES FOR ENHANCED FEATURES IN NEXT GENERATION SELF-INJECTION DEVICESBoeri, M. / Szegvari, B. / Hauber, B. / Mange, B. / Mountian, I. / Schiff, M. / Maniadakis, N. et al. | 2018
-
PCV57 - HEALTH INSURANCE COST OF HYPERTENSIVE HEART DISEASE IN HUNGARY: A NATIONWIDE COST OF ILLNESS STUDYGazsó, T. / Boncz, I. / Sebestyén, A. / Gratz, B. / Endrei, D. et al. | 2018
-
PCV37 - IDENTIFICATION OF FACTORS AFFECTING READMISSIONS IN HEART FAILURE PATIENTSAkkineni, S.S. / Mohammed, O. / Kunhikatta, V. / Kumar, J.P. / Devasia, T. et al. | 2018
-
PCP3 - ADAPTIVE PATHWAYS 2020: WHAT'S ON THE HORIZON IN THE NEXT 2-3 YEARS?Rejon-Parrilla, J.C. / Bouvy, J. et al. | 2018
-
PCP23 - DOES THE EUROPEAN UNION (EU) NEED EUROPEAN HTA OR EUROPEAN PROCUREMENT?Toumi, M. / Rémuzat, C. / Auquier, P. / Borrisov, B. / Espín, J. / Postma, M.J. / Ruggeri, M. / Wilk, N. / Simoens, S. et al. | 2018
-
PCP45 - THE ROLE OF CROSSOVER AND TREATMENT SWITCHING IN INDIRECT TREATMENT COMPARSON IN IMMUNO-ONCOLOGYIshak, K.J. / Muszbek, N. / Altincatal, A. / Sarri, G. / Schlichting, M. / Zhou, J. et al. | 2018
-
PCN372 - EVIDENCE MAP OF PATIENT REPORTED OUTCOME STUDIES IN NON-HODGKIN LYMPHOMA SINCE 1960Furber, A.M. / Martin, A. et al. | 2018
-
PCN380 - THE PROGNOSTIC SIGNIFICANCE OF HEALTH-RELATED QUALITY OF LIFE FROM CANCER RANDOMIZED CONTROLLED TRIALS: A SYSTEMATIC EVALUATION OF THE STATISTICAL METHODSMierzynska, J. / Pe, M. / Piccinin, C. / Martinelli, F. / Coens, C. / Gotay, C. / Grønvold, M. / Bjordal, K. / Velikova, G. / Tomaszewski, K. et al. | 2018
-
PCN348 - QUALITY OF LIFE IN END-STAGE CANCER DISEASEGolicki, D. / Ciećko, W. / Zarzeczna-Baran, M. / Bandurska, E. et al. | 2018
-
PCN353 - CONSTRUCT VALIDITY OF EQ-5D-3L IN NON-MELANOMA SKIN CANCER (NMSC)Gorry, C. / Boggs, J. / Barry, R. / Barry, M. / McCullagh, L. et al. | 2018
-
PCN352 - UTILITY VALUES FOR ADVANCED HEPATOCELLULAR CARCINOMA PATIENTS IN FRANCE RECEIVING SELECTIVE INTERNAL RADIATION THERAPY (SIRT) WITH Y-90 RESIN MICROSPHERES VERSUS SORAFENIB USING EQ-5D SCORES MAPPED FROM EORTC-QLQ-C30 RESULTSPatterson, K. / Hart, R. / Shergill, S. / Colaone, F. / Brennan, V. / Durand-Zaleski, I. / Vilgrain, V. / Lee, D. et al. | 2018
-
PCN327 - CHALLENGES AND OPPORTUNITIES IN CLINICAL NUTRITION IN ONCOLOGY: AVAILABLE EVIDENCE, REAL WORLD PRACTICES, AND THE WAY FORWARDGoldwasser, F. / Piaggio, T. / Lucas, J. / Zalcman, G. / Tilleul, P. / Schiefke, I. / Marschal, O. / Pedrazzoli, P. / Caccialanza, R. et al. | 2018
-
PCN293 - WHAT IS THE VALUE OF REAL WORLD EVIDENCE IN ONCOLOGY IN HTA APPRAISALS IN ENGLAND, FRANCE, CANADA AND AUSTRALIA?Ng, T. / Chawla, T. / Bending, M.W. et al. | 2018
-
HT1 - CONSEQUENCES AND VALIDITY OF AN EMPIRICAL ESTIMATION OF THE NICE COST EFFECTIVENESS THRESHOLDGrobler, M. / Lothgren, M. et al. | 2018
-
AD1 - ASSOCIATION OF ADHERENCE AND TREATMENT INTENSITY WITH CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ATHEROSCLEROSIS OR OTHER CARDIOVASCULAR RISK FACTORS TREATED WITH STATINS AND/OR EZETIMIBEKhunti, K. / Danese, M. / Kutikova, L. / Catterick, D. / Gleeson, M. / Seshasai, S.R. / Brownrigg, J. / Ray, K.K. et al. | 2018
-
PHP203 - RELATIVE VALUE OF EVIDEM MCDA FRAMEWORK FOR REFLECTIVE DRUG EVALUATION AMONG HOSPITAL PHARMACISTS IN PORTUGALMirco, A. / Paulino, E. / Farinha, M.H. / Gil, A. / Shepherd, J. / Badia, X. et al. | 2018
-
PHP194 - THE EMA CLINICAL DATA WEBSITE: A CONCEPTUAL EXPLORATORY APPROACH TO BENCHMARK CLINICAL DEVELOPMENT INDICATORS IN MARKETING AUTHORIZATIONSLehmann, S. / Allard, R. / Boehler, Y. et al. | 2018
-
PHP195 - DO COMPANIES' MARKET ACCESS TRAINING CAPABILITIES ADDRESS THE NEEDS OF TODAY'S COMPLEX PAYER MARKETPLACE?Bailey, S. / Hewitt, C. / Craddy, P. / Foxon, G. et al. | 2018
-
PHP177 - THE USAGE OF PACKAGE CRITERIA IN DUTCH REIMBURSEMENT DECISION MAKING AND THEIR INFLUENCE ON ZIN RECOMMENDATIONSvan de Rijt, J. / Severens, J.L. / van Baal, P. / Knies, S. et al. | 2018
-
PHP165 - THE LONG-TERM CHANGE OF MEDICAL SERVICE PRICE: AN INTERNATIONAL COMPARISON OF SELECTED COUNTRIESLi, L. / Liu, B. et al. | 2018
-
PHP141 - THE PRIVATE HEALTHCARE MARKET IN BRAZIL: A REVIEW OF 18 YEARS OF PROGRESSSaggia, M.G. et al. | 2018
-
PHP137 - CHANGES IN THE NUMBER OF NURSING WORKFORCE IN EUROPEAN COUNTRIES BETWEEN 2000-2015Elmer, D. / Endrei, D. / Ágoston, I. / Horváth, L. / Gratz, B. / Németh, N. / Horváthné Kívés, Z. / Boncz, I. et al. | 2018
-
PHP136 - CHANGES IN THE NUMBER OF PHYSIOTHERAPIST WORKFORCE IN EUROPEAN COUNTRIES BETWEEN 2000-2015Elmer, D. / Boncz, I. / Ágoston, I. / Horváth, L. / Molics, B. / Németh, N. / Horváthné Kívés, Z. / Endrei, D. et al. | 2018
-
PHP129 - CHALLENGES AND OPPORTUNITIES IN THE BIOLOGICALS-BIOSIMILARS MARKET: SUSTAINABILITY AND MARKET DIFFERENTIATIONGarcía-Goñi, M. / Cantarero, D. et al. | 2018
-
PHP114 - THE ERRATIC AND LONG ACCESS JOURNEY OF ORPHAN DRUGS FROM EUROPE TO PORTUGALFerreira, C. / Andreozzi, V. / Vandewalle, B. / Félix, J. et al. | 2018
-
PHP86 - IMPORTANCE OF CRITERIA FOR DRUG REIMBURSEMENT DECISION-MAKING FOR NON-LIFE-THREATENING DISEASESFunagoshi, M. / Murasawa, H. / Shiroiwa, T. / Saito, S. / Shimozuma, K. et al. | 2018
-
PHP83 - THE IMPACT OF THE NEW INNOVATIVE ALGORITHM IN ITALYUrbinati, D. / Rova, A. / Cioni, L. et al. | 2018
-
PHP54 - DIRECTIVE 2004/18/EC: IMPLICATIONS FOR PUBLIC MEDICINE PROCUREMENT IN EUROPEZegaoui, Y. / Sogokon, P. / Morrison, S. et al. | 2018
-
PHP23 - COMPARING RISK SHARING AGREEMENTS IN CATALONIA WITH OTHERS EU COUNTRIESGuarga, L. / Fondevilla, E. / Pastor, M. / Roig, M. / Cirera, J. / Llop, C. / Alonso, E. / Obach, M. / Fontanet, M. / Gasol, M. et al. | 2018
-
PGI4 - REAL-WORLD TRENDS IN CLINICAL CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS INITIATING VEDOLIZUMAB OVER TIME IN ISRAELWeil, C. / Chodick, G. / Shalev, V. / Demuth, D. / Petrakis, I. / Ben Baruch, O. / Tsukinovsky, S. / Yarden, A. et al. | 2018
-
PDB128 - COMPARISON OF PATIENT ACTIVATION LEVELS ACROSS VARIOUS CONDITIONS IN THE US AND EU5Annunziata, K. / Sternbach, N. / Carpinella, C.M. / Chapnick, J. / Patel, P. / McDonald, M. / McElwee, N. et al. | 2018
-
PDB111 - TREND AND FACTORS ASSOCIATED WITH PREVENTABLE HOSPITALIZATION AMONG DIABETES MELLITUS PATIENTS IN A NATIONAL HEALTH INSURANCE PROGRAMCheng, J. / Ku, H. / Huang, C. / Hsu, C. et al. | 2018
-
PDB102 - THERAPY ADJUSTMENT FOLLOWING DPP-4 INHIBITOR INITIATION IN T2DM PATIENTS WITH CREATININE CLEARANCE <50 ML/MIN: A RETROSPECTIVE COHORT STUDY USING DATA FROM UK GENERAL PRACTICESpanopoulos, D. / Barrett, B. / Busse, M. / Roman, T. / Poole, C. et al. | 2018
-
PDB110 - TREATMENT PERSISTENCE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH GLP-1 RECEPTOR AGONISTS IN CLINICAL PRACTICE IN SWEDEN: NATIONWIDE RETROSPECTIVE COHORT STUDYToll, A. / Eliasson, B. / Lebrec, J. / Karlsdotter, K. / Miftaraj, M. / Franzen, S. / Svensson, A. et al. | 2018
-
PHP345 - INNOVATIVE PAYMENT MODELS FOR BREAKTHROUGH THERAPIESHanna, E. / Dussart, C. / Auquier, P. / Toumi, M. et al. | 2018
-
PHP309 - HTA CAPACITY BUILDING - OPPORTUNITIES AND CHALLENGES AS RESULT OF HTA INSTITUTIONS RESEARCHGeorgiev, S. / Yanakieva, A. / Velikov, S. et al. | 2018
-
PHP320 - ANALYSIS OF HTA PROCESS ON THE BASIS OF PHARMACOECONOMIC GUIDELINES IN CENTRAL EASTERN EUROPEAN COUNTRIESSidzhimova, D. / Benisheva, T. / Boncheva, E. / Trendafilova, P. / Kralimarkov, N. et al. | 2018
-
PHP323 - ESTABLISHING AN ALIGNED VIEW OF MODERN, FORWARD-LOOKING HTA PROCESSNeri, M. / Hampson, G. / Towse, A. et al. | 2018
-
PHP302 - HOW AFFORDABILITY IS CONSIDERED FOR PRICING POLICIES?Rémuzat, C. / François, C. / Toumi, M. et al. | 2018
-
PHP295 - REVIEW OF POSSIBLE CAUSES OF VARIATION IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISALSLing, C. / Nuabor, W. / Lyall, M. / Stevenson, A. et al. | 2018
-
PHP271 - THE GROWING IMPORTANCE OF DIGITAL CHANNELS IN FORMULARY DECISION MAKING IN THE USFiglar, H. / Arnold, M. / Wray, J. / Hoskins, N. / Fletcher-Louis, M. / Casanova, C. et al. | 2018
-
PHP278 - GUIDELINES IN GERMAN EARLY BENEFIT ASSESSMENT – WHICH GUIDELINES ARE CONSIDERED BY FEDERAL JOINT COMMITTEE FOR DETERMINING THE APPROPRIATE COMPARATOR?Scheler, E. / Stratil, A. / Roxlau, T. / Bonduelle, D. et al. | 2018
-
PHP249 - ARE TRADITIONAL MANAGED ENTRY AGREEMENTS SUITABLE FOR POTENTIALLY, CURATIVE GENE/CELL THERAPIES?Colasante, W. et al. | 2018
-
PHP255 - EUROPEAN "REAL-WORLD" EVIDENCE FOR DRUGS AND DEVICES: 2017 LITERATURE REVIEWEDMordin, M. / Castro, C. / Buck, P.M. / Fernandez, M.M. / Hollis, K.A. / Ritchey, M.E. et al. | 2018
-
PHP225 - ASSESSMENT OF THE UNIT COSTS IN IMAGING ACTS: THE EXAMPLE OF MRI AND CT-SCAN ACTS IN FRANCEVasilescu, L. / Faller, M. / Allou, A. et al. | 2018
-
PDB94 - INITIAL ANTIDIABETIC PHARMACOTHERAPY PRESCRIBED TO PATIENTS WITH NEWLY DIAGNOSED TYPE-2 DIABETES IN A COMMERCIAL HEALTH PLAN IN THE UNITED STATEDAlthobaiti, H.A. / Alsheikh, M.Y. / Seoane-Vazquez, E. / Lewis, J. / Brown, L.M. et al. | 2018
-
PDB85 - A 10 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) OF THE DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPP/DPPOS): CLARIFYING THE PREVIOUS CONFUSIONAlolayan, S. / Eguale, T. / Segal, A. / Doucette, J. / Rittenhouse, B. et al. | 2018
-
PDB75 - COST-EFFECTIVENESS OF TREATING PATIENTS WITH TYPE 2 DIABETES POORLY CONTROLLED ON BASAL INSULIN WITH FIXED-RATIO COMBINATIONS OF BASAL INSULIN AND GLP-1 RECEPTOR AGONISTS IN DENMARK: IDEGLIRA VERSUS IGLARLIXIHvid, C. / Parekh, W. / Pöhlmann, J. / Hunt, B. et al. | 2018
-
PDB22 - CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS REACHING A HIGH DAILY DOSE OF IDEGLIRA SIX MONTHS AFTER INITIATION IN A REAL-WORLD SETTINGPrager, R. / Price, H. / Blüher, M. / Fernandes, J. / Møller, J.B. / Schultes, B. et al. | 2018
-
PDB25 - PRESCRIBING PATTERN IN DIABETES MELLITUS PATIENTS IN SLOVENIAJanzic, A. / Locatelli, I. et al. | 2018
-
PCV153 - ELICITING PUBLIC PREFERENCES FOR REORGANIZATION OF VASCULAR SERVICES IN THE UKWickramasekera, N. / Howard, A. / Shackley, P. et al. | 2018
-
PDB47 - THE ASSOCIATION BETWEEN RENAL FUNCTION AND HEALTHCARE COSTS IN US PATIENTS WITH TYPE 2 DIABETESLage, M.J. / Bae, J. / Mody, R. / Botros, F.T. / Wu, J. / Boye, K. et al. | 2018
-
PCV124 - HOSPITAL ADMISSIONS FOR HEART FAILURE IN ENGLAND; AN INCREASING BURDEN ON NHS RESOURCES AND THE FOCUS OF EFFECTIVE COST CONTAINMENTHickey, D.A. / Beecroft, S. et al. | 2018
-
PCV109 - ARE CARDIOVASCULAR MEDICINES IN QATAR AND LEBANON AFFORDABLE? AN ANALYSIS AND COMPARISON OF TWO DEVELOPING MIDDLE-EASTERN COUNTRIESAbdel Rida, N. / Mohamed Ibrahim, M.I. / Owusu, Y. / Babar, Z. et al. | 2018
-
PCV133 - ADHERENCE SUPPORT IN COMMUNITY PHARMACIES - THE PERCEPTION OF GERMAN PHARMACISTSLaven, A. / Nasert, S. / Katzfey, U. / Amelung, V. / Klemm, M. / Knoefler, M. / Mueller, H. / Rupprecht, C. / Unkrig, S. / Vrijens, B. et al. | 2018
-
PCV89 - CLINICAL AND ECONOMIC BURDEN OF IRON DEFICIENCY IN PATIENTS WITH CHRONIC HEART FAILUREFerreira, C. / Vandewalle, B. / Félix, J. / Gomes, S.O. et al. | 2018
-
PCN255 - CERVICAL AND BREAST CANCER IN KAZAKHSTAN BEFORE AND AFTER THE INTRODUCTION OF SCREENING: AN INTERRUPTED TIME SERIES ANALYSISSultanov, M. et al. | 2018
-
PCN272 - ANALYSIS OF PHARMACY CLAIMS FOR HIGH COST DRUGS: LENALIDOMIDE UTILISATION AND EXPENDITURE IN IRELANDMcCabe, L. / Moloney, D. / Barry, M. / Usher, C. / McCullagh, L. et al. | 2018
-
PCN269 - HEALTHCARE RESOURCE USE (HRU) ASSOCIATED WITH TREATMENT IN ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) RELAPSED OR REFRACTORY (R/R) B-CELL PRECURSOR (BCP) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN EU-4 COUNTRIESZhang, X. / Zhang, L. / Gijsen, M. / Cong, Z. et al. | 2018
-
PCN214 - IBRITUMOMAB TIUXETAN RADIOLABELLED WITH YTTRIUM CHLORIDE: 4 YEARS OF USE IN THE 37 PUBLIC HOSPITALS OF PARIS AND IN FRANCEGérard, C. / Therasse, C. / Cordonnier, A. / Degrassat-Théas, A. / Paubel, P. / Fusier, I. et al. | 2018
-
PCN241 - OLAPARIB USE AND TREATMENT OUTCOMES IN SWEDISH PATIENTS TREATED DURING THE FIRST THREE YEARS FOLLOWING REGULATORY APPROVALEriksson, I. / Wettermark, B. / Bergfeldt, K. et al. | 2018
-
PCN264 - ASSESSMENT OF TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN SPAIN FOLLOWING INITIAL PLATINUM THERAPY FOR RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)Parikh, R.C. / Kurosky, S. / Kaye, J.A. / Levine, C. / Hettle, R. / Shire, N. / Sawyer, W. / Wang, H. et al. | 2018
-
PCN198 - AN ECONOMIC SYSTEMATIC LITERATURE REVIEW (SLR) FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) NON-SMALL-CELL LUNG CANCER (NSCLC)Robson, R.E. / Cranmer, H. / Huang, J. / Selby, R. / Lin, H.M. / Tolley, K. et al. | 2018
-
PCN136 - A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN CANADALakhdari, K. / Young, K.C. / Holdgate, O. / Doan, J. et al. | 2018
-
PCN133 - THE SOCIETAL IMPACT OF OBINUTUZUMAB IN THE FIRST LINE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA IN GERMANYHofmann, S. / Ostwald, D.A. / Himmler, S. / Launonen, A. / Dünzinger, U. / Salmen, H. et al. | 2018
-
PCN167 - IMPROVEMENT OF AN OPEN-SOURCE COST-EFFECTIVENESS MODEL BASED ON PUBLIC FEEDBACKIncerti, D. / Shafrin, J. / Lakdawalla, D.N. / Zhao, L. / Linthicum, M. / Jansen, J.P. et al. | 2018
-
PCN127 - DIRECT HEALTHCARE COSTS BY TREATMENT AMONG PATIENTS WITH MERKEL CELL CARCINOMA (MCC) IN THE UNITED STATESKearney, M. / Thokagevistk, K. / Boutmy, E. / Sherman, S. / Bharmal, M. et al. | 2018
-
PCN129 - TREATMENT COSTS AND PROGRESSION-FREE SURVIVAL OF DVD AND KRD REGIMENS SEQUENCES IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEMRosim, R.P. / Julian, G. / Mendes, A. / Ricco, M. / Fioratti, C.O. / Scaccabarozzi, L. et al. | 2018
-
PCN84 - TOTAL COST OF CARE AND BUDGET IMPACT FOR PATIENTS WITH CLL TREATED WITH VENETOCLAXCho, S.K. / Samp, J.C. / Keim, H. / Masaquel, A.S. / Johnson, S.J. / Parise, H. et al. | 2018
-
PCN117 - HEALTHCARE EXPENDITURES FOR THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IN JAPANFukuda, H. / Ishida, H. / Sato, D. / Moriwaki, K. et al. | 2018
-
PCN99 - EVALUATING THE INCREASING STRAIN OF IMMUNOTHERAPIES (PD-1/PD-L1) ON PUBLIC HEALTHCARE SYSTEMS IN T5 + USDe Cristofano, F. / Barling, H.D. / Bell, C. et al. | 2018
-
PCN77 - BUDGET IMPACT ANALYSIS OF BLINATUMOMAB FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA NEGATIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN MEXICOAlva, M.E. / Ortíz, M. / Flores, B. et al. | 2018
-
PCN72 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN ENGLANDHollmann, S. / Painter, C. / Hogan, A. / Morten, P. / Goyert, N. / Vieira, J. / Slowley, A. / Jousseaume, E. / El Ouagari, K. / Zhang, J. et al. | 2018
-
PCN34 - PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NSCLC – A NETWORK META-ANALYSISFrederickson, A.M. / Arndorfer, S. / Lorenzi, M. / Insinga, R. / Chandwani, S. / Burke, T. et al. | 2018
-
PCN46 - DURABLE THERAPY IN FRONTLINE CLL IMPROVES OSBaculea, S. / Horsburgh, S. / Chadda, S. / Nelson, L. / LeReun, C. et al. | 2018
-
PCN28 - A REVIEW OF THE EFFECTIVENESS OF PHOTODYNAMIC THERAPY FOR CANCERKirsanova, O. / Sukhorukikh, O. et al. | 2018
-
PCV45 - BUDGET IMPACT ANALYSIS OF ACEI AND ARBS II DRUGS IN PATIENTS WITH ARTERIAL HYPERTENSIONTolordava, G. / Yagudina, R. / Arinina, E. et al. | 2018
-
PCV23 - TIME TO TREATMENT INTENSIFICATION IN NEW STATIN USERSMachado-Duque, M. / Gaviria-Mendoza, A. / Machado-Alba, J. et al. | 2018
-
PCN376 - EXAMINING CANCER RELATED DISTRESS AMONG A GROUP OF URBAN-DWELLING VETERANS.Azizoddin, D. / Rynar, L. / Molokie, R. / Hauser, J. / Payvar, S. / Martin, J. et al. | 2018
-
PCP4 - DEVELOMENT OF A QUALITY MANAGEMENT SYSTEM FOR EUNETHTA AND THE PERMANENT EUROPEAN COLLABORATION ON HTAFathollah-Nejad, R. / Luhnen, M. / Rehrmann, M. et al. | 2018
-
PCN366 - QUALITATIVE PATIENT INTERVIEWS TO SUPPORT THE FACT HEPATOBILIARY SYMPTOM INDEX-8 AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEINGable, J. / Ayer, D. / Girvan, A. / Bowman, L. / Abada, P. / Ervin, C. / Evans, E. / Cella, D. et al. | 2018
-
PCP8 - BENELUXA INITIATIVE: WHY THE FIRST ATTEMPT OF JOINT ASSESSMENT FAILED?Pisarczyk, K. / Rémuzat, C. / Hajjeji, B. / Toumi, M. et al. | 2018
-
PCN361 - HEALTH ECONOMIC VALUE PROPOSITIONS FOR SUBCUTANEOUS TRASTUZUMAB AND THEIR TRANSFERABILITY TO CENTRAL-EASTERN EUROPEAN COUNTRIESInotai, A. / Ágh, T. / Karpenko, A.W. / Zemplényi, A. / Kaló, Z. et al. | 2018
-
PCP2 - IS DIGITAL TECHNOLOGY BRINGING THE ADOPTERS CLOSER TO THE DECISION-MAKERS: A COMPARATIVE ASSESSMENT ACROSS FIVE EUROPEAN MARKETS.Khan, S. / Teale, C.W. / Heupel, M. / Czira, A. et al. | 2018
-
PCN381 - REFERENCE VALUES FOR EORTC QLQ-C30 IN HODGKIN'S LYMPHOMAMierzynska, J. / Taye, M. / Pe, M. / Coens, C. / Martinelli, F. / Flechtner, H. / Meijnders, P. / Lugtenburg, P.J. / Shepherd, L. / Hertzberg, M. et al. | 2018
-
PCN324 - EXAMINING HPV VACCINATION PRACTICES AND DIFFERENCES AMONG PROVIDERS IN VIRGINIAAlcalá, H.E. / Maxwell, G.L. / Keim-Malpass, J. / Mitchell, E. / Balkrishnan, R. et al. | 2018
-
PCN314 - HEALTH-TECHNOLOGY ASSESSMENTS IN ONCOLOGY: RESULTS OF A REVIEW OF DECISIONS IN GERMANYGottschalk, F. / Mueller, S. / Wilke, T. et al. | 2018
-
PCN302 - IS THE NEW NICE APPRAISAL PROCESS FOR ONCOLOGY INDICATIONS TOO POSITIVE IN ITS ASSESSMENT OF CANCER DRUGS IN ENGLAND?Chunara, F. / Foxon, G. / Craddy, P. et al. | 2018
-
DB3 - PROOF-OF-CONCEPT STUDY OF DIGITAL SMARTPHONE APPLICATIONS TO SUPPORT SELF-MANAGEMENT OF LONG-TERM HEALTH CONDITIONSSmith, W. / Orlowski, A. / Itrakjy, A. / Porter, A. / Willis, T. et al. | 2018
-
CE4 - COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCERHolleman, M.S. / Al, M.J. / Uyl-de Groot, C.A. et al. | 2018
-
AD2 - A FULLY INTEGRATED CLINICAL TRIAL LIKE SYSTEM TO GUARANTEE PERSISTENCE ON PLANNED HEPATITIS C TREATMENT: EVIDENCE FROM THE REAL-WORLDGomes, I. / Figueira, A. / Sequeira, C. / Silva, S. / Machado, F. / Figueiredo, J. / Rabadão, E. / Granjeia, R. / Andreozzi, V. / Félix, J. et al. | 2018
-
Editorial Board| 2018
-
PCN394 - PRICES AND COSTS OF CANCER TREATMENTS IN FRANCE: REALITIES, CHALLENGES AND PERSPECTIVESBaseilhac, E. / Dorizon, D. / Heng, C. et al. | 2018
-
PCV157 - ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND ATRIAL FIBRILLATION SYMPTOM BURDEN: RESULTS OF A STUDY ON ATRIAL FIBRILLATION PATIENTS IN GERMANY, SWEDEN AND SWITZERLANDWilke, T. / Bloempott, S. / Henry, M. / Mueller, S. et al. | 2018
-
PIN19 - A COST COMPARISON OF TREATING CHRONIC HEPATITIS C PATIENTS WITH SOFOSBUVIR-BASED REGIMENSRu, H. / Zhou, J. et al. | 2018
-
PIH50 - RESILIENCE AND ITS INFLUENCING FACTORS' EFFECT ON TIMELY APPEARENCE OF 2ND AND 3RD PHASE OF LACTOGENESISKarácsony, I. / Balogh, B. / Szabó, L. / Oláh, A. / Ipolyi, D. / Brantmüller, É. / Boncz, I. / Pakai, A. et al. | 2018
-
PIH4 - HEALTHCARE RESOURCE USE AND COSTS ASSOCIATED WITH EXTREMELY PRETERM BIRTH IN THE NETHERLANDSHouben, E. / Siffel, C. / Overbeek, J.A. / Sarda, S.P. et al. | 2018
-
PHP356 - COMPARATIVE ANALYSIS BETWEEN OLD AND NEW ITALIAN INNOVATION RATING SYSTEMPrada, M. / Sansone, C. / Mariano, E.E. / Mantovani, M. et al. | 2018
-
PHP360 - THE EFFECT OF EUNETHTA ASSESSMENTS ON NATIONAL HTA DECISION MAKINGChew, V.C. / Sogokon, P. / McNamara, L. / Morrison, S. et al. | 2018
-
PDB137 - COMPARISON OF ORAL ANTIDIABETIC DRUGS AS ADD-ON TREATMENTS IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON METFORMIN: A NETWORK META-ANALYSISSitu, B. et al. | 2018
-
PGI52 - DECREASED WORK PRODUCTIVITY AND INCREASED HEALTHCARE RESOURCE UTILISATION (HRU) AMONG PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) – RESULTS FROM A REAL WORLD EVIDENCE STUDYKnight, A. / Balp, M. / Mckenna, S.J. / Przybysz, R. / Cai, J. / Brass, C. / Howe, T. / Rosen, D. / Gavaghan, M. / Vazquez, V.C. et al. | 2018
-
PIN20 - A COST-EFFECTIVENESS ANALYSIS OF THE INFLUENZA VACCINE IN ADULT PATIENTS WITH CANCERShields, G.E. / Cranmer, H. / Camacho, C. / Porter, J.K. et al. | 2018
-
PIN22 - A PAYER PERSPECTIVE OF THE HOSPITAL INPATIENT ADDITIONAL CARE COSTS OF ANTIMICROBIAL RESISTANCE IN FRANCE: A MATCHED CASE-CONTROL STUDYTouat, M. / Brun-Buisson, C. / Opatowski, M. / Cosker, K. / Guillemot, D. / Salomon, J. / Tuppin, P. / de Lagasnerie, G. / Watier, L. et al. | 2018
-
PIN12 - HOSPITALIZATIONS RELATED TO RESPIRATORY VIRAL INFECTIONS DURING THE 2017/18 SEASON IN THE VALENCIA REGION OF SPAINMira-Iglesias, A. / Baselga-Moreno, V. / López-Labrador, F.X. / Díez-Domingo, J. et al. | 2018
-
PIH51 - THE EFFECT OF EXERCISING ON SEXUAL FUNCTIONS IN POST-MENOPAUSAL WOMENNovák, E. / Oláh, A. / Vajda, R. / Csákvári, T. / Boncz, I. / Ferenczy, M. / Kiss, T. / Radics, L. / Pakai, A. et al. | 2018
-
PIH29 - DEVELOPMENT OF A DECISION AID PROTOTYPE FOR PARENTS CONSIDERING TUBE FEEDING FOR THEIR CHILDRENRivero, C. / Rodriguez, A. / Moreno, A. / Vives, I. / Layola, M. / Gabás-Rivera, C. / Aceituno, S. et al. | 2018
-
PIH34 - PROGRAM 75+ - FREE MEDICINES FOR THE ELDERLYPlisko, R. / Rutkowski, J. et al. | 2018
-
PIH30 - ASSESSMENT OF TREATMENT PATTERN IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME (PCOS) IN A TERTIARY CARE HOSPITAL IN URBAN SETTINGKrishna Murthy, M. / Ravi, R. / Jose, S.A. / Pudi, C. / Koonisetty, K.S. / Minnikanti, S.S. et al. | 2018
-
PIN5 - 10 YEARS OF HUMAN PAPILLOMAVIRUS SYSTEMATIC VACCINATION IN SPAIN: FORECASTING HEALTH OUTCOMES CONSIDERING AS04-HPV16/18 VACCINE EFFECTIVENESS DATAMorano, R. / Cambronero, Md / López Sanromá, M. et al. | 2018
-
PIH21 - BUDGET IMPACT OF A NEW INTRAUTERINE SYSTEM IN PORTUGALMaia-Lopes, S. / Pissarra, M. / André, S. et al. | 2018
-
PIH6 - DEVELOPMENT AND VALIDATION OF A SCREENING QUESTIONNAIRE TO DETECT HEAVY MENSTRUAL BLEEDING IN GYNAECOLOGY: THE SAMANTA QUESTIONNAIRERius, J. / Carrasco, M. / Pujol, P. / Catafal, G. / Perelló, J. / Calaf, J. et al. | 2018
-
PIH11 - ANTIEMETIC USE IN PREGNANCY AND THE RISK OF MAJOR CONGENITAL MALFORMATIONS: A POPULATION-BASED COHORT STUDYBérard, A. / Sheehy, O. / Gorgui, J. / Zhao, J. / Moura, C. / Bernatsky, S. et al. | 2018
-
PHP218 - HOW HIGH CAN YOU GO? - THE IMPACT OF INDICATION EXPANSION AND MARKET COMPETITION ON DRUG PRICES IN THE EU5Radu, X. / Damera, V. / Martin, M. et al. | 2018
-
PHP201 - DEVELOPMENT OF MEDICATION SAFETY STANDARDS IN SELECTED HOSPITALS IN IRANIzadpanah, F. / Nikfar, S. / Bakhshi Imcheh, F. / Zargaran, M. et al. | 2018
-
PHP208 - PHYSICIANS' IMPROVEMENT SUGGESTIONS FOR ENTERAL NUTRTION CARE IN CHINA: A CROSS-SECTIONAL SURVEYSuo, S. / Ung, C.O. / Shi, H. / Chen, S. / Hu, H. et al. | 2018
-
PHP150 - GEOGRAPHICAL VARIABILITY IN THE UTILIZATION OF SERVICES AND PHARMACEUTICAL EXPENDITURE BY ADVANCED CHRONIC PATIENTSDíaz-Carnicero, J. / Uso-Talamantes, R. / Bertomeu-Izquierdo, L. / Trillo Mata, J.L. / Vivas, D. et al. | 2018
-
PHP153 - KEY STAKEHOLDERS PERCEPTIONS OF HEOR USAGE IN LEBANONMesmar, A. / Maskineh, C. / Becker, R.V. et al. | 2018
-
PHP146 - ANALYSES OF THE PERFORMANCE INDICATORS OF REHABILITATION AND CHRONIC INPATIENT CARE IN HUNGARY BETWEEN 1990 AND 2016Ágoston, I. / Endrei, D. / Molics, B. / Szarka, E. / Gyuró, M. / Komáromy, M. / Boncz, I. et al. | 2018
-
PHP133 - TOWARDS IMPLEMENTING MEDICATION THERAPY MANAGEMENT SERVICE IN MALAYSIA: PERCEPTIONS AND CHALLENGESAl-Tameemi, N.K. / Sarriff, A. et al. | 2018
-
PHP116 - TREND IN OPIOID USE FROM 2001 THROUGH 2013 AMONG ELDERLY US VETERANSDwibedi, N. / Rowneki, M. / Shen, C. / Helmer, D. / Sambamoorthi, U. et al. | 2018
-
PHP97 - NONADHERENCE TO TACROLIMUS IN ADULT LIVER AND KIDNEY TRANSPLANTATION IS ASSOCIATED WITH A HIGHER RISK OF EFFICACY FAILURE: REAL-WORLD EVIDENCE FROM ITALIAN ADMINISTRATIVE DATABASESVeronesi, C. / Biancone, L. / Burra, P. / De Simone, P. / Grandaliano, G. / Rigotti, P. / Tisone, G. / Perrone, V. / Degli Esposti, L. et al. | 2018
-
PHP80 - HOW CLASSIFICATION OF CELL AND GENE THERAPIES AS DRUGS, DEVICES OR PROCEDURES COULD HAVE SIGNIFICANT IMPLICATIONS FOR THEIR PRICING AND REIMBURSEMENT AND COMMERCIAL SUCCESSMacaulay, R. / Wang, G.D. / Rothwell, S. et al. | 2018
-
PHP58 - SPANISH THERAPEUTIC POSITIONING REPORTS: 6-YEAR UPDATE – INCREASING IN FREQUENCY BUT NOT RELEVANCE?Macaulay, R. / Fernandez Dacosta, R. et al. | 2018
-
PHP65 - ANALYSIS OF ICER-ESTIMATED VALUE-BASED PRICES AND POTENTIAL DISCOUNTS FOR DRUGS IN THE UNITED STATESKloc, K. / Dusza, M. / Lach, S. / Sediri, Y. / Rémuzat, C. / Toumi, M. et al. | 2018
-
PHP50 - PRICE REGULATION ORDINANCE IMPACT ON REIMBURSED PRICES FOR MOSTLY PRESCRIBED MEDICINES IN BOSNIA AND HERZEGOVINAČatić, T. / Jusufović, R. / Tabakovic, V. et al. | 2018
-
PHP21 - METHODOLOGY OF IDENTIFICATION OF RISK GROUPS UNDER PHARMACEUTICAL GUIDELINES IN A SPECIAL REGIME INSURER IN COLOMBIARomero, M. / Gallo, D. / Silva, E. et al. | 2018
-
PHP47 - EVALUATING PATIENTS', PHYSICIANS' AND PHARMACISTS' PERCEPTION REGARDING GENERIC MEDICINES IN GONDAR, NORTHWEST ETHIOPIAGebresillassie, B.M. et al. | 2018
-
PHP30 - THE CONTRIBUTION OF NEW PRODUCT ENTRY VS EXISTING PRODUCT INFLATION IN THE RISING COSTS OF PRESCRIPTION DRUGS IN THE UNITED STATESHernandez, I. / Good, C.B. / Cutler, D. / Gellad, W.F. / Parekh, N. / Shrank, W.H. et al. | 2018
-
PGI33 - URSODEOXYCHOLIC ACID TO GALLSTONE DISSOLUTION THERAPY IN ASYMPTOMATIC CHOLELITHIASIS PATIENTS: A SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETYSenna, K. / Santos, M. / Parreira, V. et al. | 2018
-
PGI23 - COST-EFFECTIVENESS ANALYSIS OF PARENTERAL METHOTREXATE FOR THE TREATMENT OF CROHN'S DISEASE IN THE CZECH REPUBLICMlcoch, T. / Hajickova, B. / Ornstová, E. / Chadimova, K. / Bartakova, J. / Dolezal, T. et al. | 2018
-
PDB127 - APPLICATION OF BEST WORST SCALING TO IMPROVE PATIENT-CENTERED TREATMENT DECISIONS IN DIABETIC PERIPHERAL NEUROPATHYAdams, A.S. / Prosser, L. / Altschuler, A. / Ma, L. / Wittenberg, E. et al. | 2018
-
PDB103 - FINANCIAL ACCESS TO HEALTH CARE USE IN DIABETICS WITH HIGH-DEDUCTIBLE HEALTH PLAN (HDHP)Yao, J. / Li, M.S. / Lu, K. et al. | 2018
-
PDB134 - CHARACTERISTICS OF US ADULTS WITH CONTROLLED AND UNCONTROLLED TYPE 2 DIABETESMorlock, A. / Dobrescu, R. et al. | 2018
-
PHP352 - SUCCESS FACTORS FOR THE IMPLEMENTATION OF MARKET ACCESS AGREEMENTS IN EMERGING MIDDLE-INCOME MARKETS IN PREPARATION FOR OUTCOMES BASED CONCEPTSBayard, J.K. / Gretsch, K. / Hallal, Z. / Stojkovic, N.S. / Strydom, J. et al. | 2018
-
PHP339 - MINIMALLY IMPORTANT DIFFERENCE (MID) OF EQ-5D-5L INDEX SCORE IN HONG KONG ADULTS POPULATION USING HONG KONG SCORING ALGORITHMWong, E.L. / Cheung, A.W. / Yau, P.S. / Wong, A.Y. / Xu, H. / Ramos Goñi, J.M. / Rivero-Arias, O. et al. | 2018
-
PHP336 - THE PRESCRIPTION COST ANALYSIS AS A TOOL TO INFORM HEALTHCARE RESOURCE ALLOCATION AND ACCESS TO PHARMACEUTICALS IN ENGLANDJohnson, K.I. / Jones, C. / Zabala Mancebo, J. et al. | 2018
-
PHP311 - UPTAKE OF JOINTLY PRODUCED EUNETHTA HEALTH TECHNOLOGY ASSESSMENTS: WHERE ARE WE NOW?Garrett, Z. et al. | 2018
-
PHP310 - COMPARISON OF THE HEALTH TECHNOLOGY ASSESSMENT OFFICES OF HUNGARY AND POLAND BASED ON OBJECTIVE CRITERIANemeth, B. / Krupa, D. / Staniak, A. / Józwiak-Hagymásy, J. / Vokó, Z. et al. | 2018
-
PHP300 - HEALTH TECHNOLOGY ASSESSMENT ROADMAP FOR UKRAINE - THE PERSPECTIVE OF STAKHOLDERS ON CURRENT STATUS AND FUTURE OPPORTUNITIESCsanádi, M. / Inotai, A. / Németh, B. / Oleshchuk, O. / Lebega, O. / Brodovskaya, A. / Piniazhko, O. / Kaló, Z. et al. | 2018
-
PHP273 - A REVIEW OF ISSUES AFFECTING THE EFFICIENCY OF DECISION MAKING IN THE NICE SINGLE TECHNOLOGY APPRAISAL PROCESSWalton, M.J. / O'Connor, J. / Carroll, C. / Biswas, M. / Claxton, L. / Hodgson, R. et al. | 2018
-
PHP259 - PHARMACOECONOMIC GUIDELINES RECOMMENDATION FOR TURKEY CONSIDERING REFERENCE COUNTRIESMihajlovic, J. / Yeğenoğlu, S. / Sozen Sahne, B. / Postma, M. et al. | 2018
-
PHP226 - VALUE-BASED PRICING WHEN THE VALUE DIFFERS BETWEEN INDICATIONS – WHAT IS THE GERMAN WAY?Witte, J. / Greiner, W. et al. | 2018
-
PDB96 - APPLYING MCDA FRAMEWORK IN PHARMACEUTICAL POLICY DECISION MAKING: A PILOT STUDY IN DIABETES MELLITUS TYPE 2Comellas, M. / Santiago, C. / Gasol, M. / Navarro, J. / Uso-Talamantes, R. / Fernandez, I. / Lizán, L. et al. | 2018
-
PDB49 - TYPE 2 DIABETES MELLITUS IN ALGERIA – A COST OF ILLNESS STUDYOulad abdallah, R. / Boukana, R. / Loumi, W. / Nebchi, E. / Mimene, A. et al. | 2018
-
PDB44 - THE HEALTH ECONOMIC VALUE OF SHORT-TERM CARDIOVASCULAR BENEFITS ASSOCIATED WITH SGLT-2I FROM CVD-REALWard, T. / Bennett, H. / McEwan, P. / Edmonds, C. / Kartman, B. / Fenici, P. / Thuresson, M. / Kosiborod, M. et al. | 2018
-
PDB3 - THE IMPACT OF GLYCATED HEMOGLOBIN CONTROL ON MORBIDITY AND SURVIVAL AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUSHammad, M.A. / Syed Sulaiman, S.A. / Qamar, M. / Shaikh, F.A. / Mohamed Noor, D.A. et al. | 2018
-
PCV138 - TREATMENT PATTERNS OF PATIENTS WITH VENOUS THROMBOEMBOLISM TREATED WITH ORAL ANTICOAGULANTS IN ENGLANDCarroll, R. / Lambrelli, D. / Donaldson, R. / Schultze, A. / Nordstrom, B. / Stynes, G. / Ramagopalan, S. / Alikhan, R. et al. | 2018
-
PCV121 - PERFORMANCE INDICATORS OF CARDIAC REHABILITATION IN HUNGARYEndrei, D. / Sebestyén, A. / Ágoston, I. / Csákvári, T. / Kovács, G. / Nogel, M. / Boncz, I. et al. | 2018
-
PCV126 - A COST-EFFECTIVENESS THRESHOLD BASED ON THE MARGINAL RETURNS OF CARDIOVASCULAR HOSPITAL SPENDINGvan Baal, P. / Perry-Duxbury, M. / Bakx, P. / Versteegh, M. / van Doorslaer, E. / Brouwer, W. et al. | 2018
-
PCV101 - HYPERTRIGLYCERIDEMIA AND RISK OF ALL-CAUSE MORTALITY AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) EVENTS IN CLINICAL PRACTICE: THE TG-REAL STUDYVeronesi, C. / Arca, M. / Borghi, C. / Colivicchi, F. / De Ferrari, G. / Desideri, G. / Pontremoli, R. / Temporelli, P. / Perrone, V. / Degli Esposti, L. et al. | 2018
-
PCV105 - POTENTIAL REDUCTION IN MORTALITY AND HOSPITALISATIONS WITH OPTIMAL USAGE OF SACUBITRIL/VALSARTAN THERAPY FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN IRELANDO'Brien, S. / Sweeney, C. / Carney, P. et al. | 2018
-
PCV94 - NUTILIS CLEAR® IN DYSPHAGIC ADULT STROKE PATIENTS WITH ASPIRATION OF 10–14 POINTS ON GUSS SCALEPelczarska, A. / Jakubczyk, M. / Niewada, M. / Lipka, I. et al. | 2018
-
PCV82 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPOREDeclan, L. / Tang, Z.X. / Ng, C. / Tan, J. / Trueman, D. / Woodcock, F. / Cristino, J. et al. | 2018
-
PCV93 - COST-EFFECTIVENESS OF GUIDELINE ADHERENCE IN CORONARY PATIENTS: THE IMPACT OF THE METHODOLOGYDe Smedt, D. / Annemans, L. / Kotseva, K. / Wood, D. / De Backer, G. / Rydén, L. / De Bacquer, D. et al. | 2018
-
PCV79 - REAL-WORLD COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH VITAMIN K ANTAGONISTS IN THE CONTEXT OF STROKE PREVENTION IN ATRIAL FIBRILLATION IN FRANCEBowrin, K. / Briere, J. / Millier, A. / Levy, P. / Clay, E. / Toumi, M. et al. | 2018
-
PCN243 - POST-LOE PRICING DYNAMICS IN ONCOLOGY: IMPACT OF MANDATORY PRICE DISCOUNTS ON LIST PRICES AND GENERIC UPTAKESeitlinger, J. / Flostrand, S. et al. | 2018
-
PCN271 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH BREAST CANCER IN SPAINCallejo-Velasco, D. / Gómez-Navarro, V. / Solozabal, M. / Planellas, L. / Carreño-Serra, A. / Á, Baltasar-Sanchez et al. | 2018
-
PCN265 - END OF LIFE CANCER CHEMOTHERAPY: A RETROSPECTIVE STUDY DURING INTENSIVE CARE UNIT (ICU) STAYReis Neto, J.P. / Busch, J.M. et al. | 2018
-
PCN229 - COMPARISON OF SICKNESS BENEFIT AND SICK LEAVE DURATION IN ONCOLOGY ACROSS COUNTRIESContente, M. / Singh, P. / Smela-Lipińska, B. / van Dijk, B. / François, C. et al. | 2018
-
PCN247 - TREATMENT PATTERNS IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (R/M SCCHN) POST PLATINUM-BASED THERAPY (PPBT) IN THE IMMUNO-ONCOLOGY (IO) ERARadtchenko, J. / Korytowsky, B. / Abraham, P. / Singh, P. / Feinberg, B.A. et al. | 2018
-
PCN202 - IMPACT OF COMORBID DEPRESSION ON RATES, COSTS, AND HEALTH CARE RESOURCE USE IN BREAST CANCER PATIENTSChung, J. / Merritt, N. / Kish, J. / Nabhan, C. / Feinberg, B.A. et al. | 2018
-
PCN219 - CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC HORMONE RECEPTOR POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE (HER2-) BREAST CANCER IN CLINICAL PRACTICE: RETROSPECTIVE ANALYSIS FROM LEEDS CANCER CENTRECheeseman, S. / Thompson, M. / Riaz, M. / Twelves, C. / Perren, T. / Ahat-Donker, N. / Sopwith, W. / Myland, M. / Lee, A. / Przybysz, R. et al. | 2018
-
PCN220 - END-OF-LIFE CARE IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDSLeeneman, B. / Franken, M. / Aarts, M.J. / van Akkooi, A.C. / van den Berkmortel, F.W. / van den Eertwegh, A.J. / de Groot, J.W. / Herbschleb, K.H. / van der Hoeven, K.J. / Hospers, G.A. et al. | 2018
-
PCN185 - COST-EFFECTIVENESS OF NIVOLUMAB IN SECOND-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA IN ADULTS AFTER FAILURE OF PRIOR PLATINUM-CONTAINING THERAPY IN GREECEBoukouvalas, S. / Diamantogiannis, F. / Basta, E. / Stephens, S. et al. | 2018
-
PCN190 - COST-EFFECTIVENESS OF NIVOLUMAB + IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDSKlijn, S. / Van de Wetering, G. / Malcolm, B. / Dale, P. / Pompen, M. / Stevanovic, J. et al. | 2018
-
PCN162 - DENOSUMAB VERSUS BISPHOSPHONATES FOR THE TREATMENT OF BONE METASTASES FROM SOLID TUMORS: A SYSTEMATIC REVIEW OF ECONOMIC STUDIESMatuoka, J. / Kahn, J. / Secoli, S.R. et al. | 2018
-
PCN156 - PHARMACOECONOMICS OF NIMOTUZUMAB IN PATIENTS WITH HEAD AND NECK CANCER IN CUBAPérez, L. / Collazo, M.M. / Iznaga, N. / García, A. et al. | 2018
-
PCN149 - COST-EFFECTIVENESS OF BRCA1/2 MUTATION PROFILING TO TARGET OLAPARIB USE IN PATIENTS WITH METASTATIC BREAST CANCER IN JAPANSaito, S. / Nakazawa, K. / Nagahashi, M. / Akazawa, K. et al. | 2018
-
PCN137 - THE ECONOMIC EVALUATION OF IMATINIB COMBINED WITH CHEMOTHERAPY FOR PEDIATRIC PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINAWang, V.W. / Li, Z. et al. | 2018
-
PCN144 - COST-EFFECTIVENESS OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF PRIOR THERAPY IN SOUTH KOREAKim, S. / Han, S. / Kim, H. / Suh, H.S. et al. | 2018
-
PCN109 - EVALUATION OF THE FACTORS AFFECTING THE COST OF PALLIATIVE CARE AT A UNIVERSITY HOSPITALSozmen, M.K. / Koç, E.M. / C.A.N., H. / Kaplan, Y.C. et al. | 2018
-
PCN68 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN ENGLANDHollmann, S. / Painter, C. / Hogan, A. / Wickstead, R.M. / Goyert, N. / Patel, S. / Slowley, A. / Jousseaume, E. / El Ouagari, K. / Zhang, J. et al. | 2018
-
PCN65 - LONG- TERM SURVIVAL AMONG PATIENTS WITH HIGH-GRADE GLIOMA TREATED WITH NIMOTUZUMABSanchez, L. / Lorenzo-Luaces, P. / Viada Gonzalez, C. et al. | 2018
-
PCN32 - THE EFFECTIVENESS AND SAFETY OF SWITCHING FROM ORGINAL FILGRASTIM TO BIOSIMILAR FILGRASTIM IN PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA: A RETROSPECTIVE COHORT STUDYAl Rabayah, A.A. / Hammoudeh, S. / Mashni, O. / Hanoun, E. / Al Qasem, W. / AL momani, D. et al. | 2018
-
PCN63 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING MATCHING-ADJUSTED INDIRECT COMPARISONS AND SIMULATED TREATMENT COMPARISONSMuresan, B. / Hu, Y. / Postma, M.J. / Ouwens, M.J. / Heeg, B. et al. | 2018
-
PCN26 - ASSESSING THE POTENTIAL VALUE OF AN INNOVATIVE ONCOLOGY THERAPY FROM THE HEALTH TECHNOLOGY ASSESSMENT (HTA) PERSPECTIVE: MARRYING CLINICAL VALUE FRAMEWORKS WITH ECONOMIC ASSESSMENT METHODOLOGYZheng, Y. / Lanitis, T. / Ambavane, A. / Proskorovsky, I. / Bharmal, M. / Phatak, H. et al. | 2018
-
PCN11 - GLOBAL LONGITUDINAL ASSESSMENT OF TREATMENT OUTCOMES IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (GLANCE-H&N) STUDYGruenwald, V. / Chirovsky, D. / Cheung, W. / Bertolini, F. / Ahn, M. / Yang, M. / de Castro, G. / Berrocal, A. / Sjoquist, K. / Kuyas, H. et al. | 2018
-
DB4 - COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN ADULT PATIENTS WITH INADEQUATELY CONTROLLED TYPE 1 DIABETES: A HEALTH ECONOMIC ANALYSIS USING 24-WEEK RESULTS FROM THE DEPICT-1 RANDOMISED CONTROLLED TRIALBennett, H. / McEwan, P. / Evans, M. / Tank, A. et al. | 2018
-
PCV25 - LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF STATIN INTOLERANT PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALYGazzi, L. / Fanelli, F. / Heiman, F. / Di Filippo, A. / Pegoraro, V. et al. | 2018
-
PCV59 - HEALTH INSURANCE COST OF ESSENTIAL (PRIMARY) HYPERTENSION IN HUNGARY: A NATIONWIDE, REAL-WORLD COST OF ILLNESS STUDYEndrei, D. / Sebestyén, A. / Gazsó, T. / Zemplényi, A. / Gratz, B. / Boncz, I. et al. | 2018
-
PCV47 - PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONSZyryanov, S. et al. | 2018
-
PCV56 - CLINICAL AND ECONOMIC BURDEN OF CARDIOVASCULAR DISEASE AND VALUE OF EVOLOCUMAB TREATMENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN SWEDENHaines, P. / Sorio-Vilela, F. / Sandelin, R. / Villa, G. et al. | 2018
-
PCP63 - DETERMINING THE OPTIMAL COST-EFFECTIVENESS CUTOFF FROM FIRST PRINCIPLES OF ECONOMICSPhelps, C.E. et al. | 2018
-
PCV19 - PATTERNS OF ANTICOAGULATION CONTROL AND CLINICAL OUTCOMES IN ATRIAL FIBRILLATION PATIENTS TREATED WITH VITAMIN K ANTAGONISTS: A REAL-WORLD STUDY USING POPULATION-BASED DATA AND GROUP-BASED TRAJECTORY MODELSGarcia-Sempere, A. / Santaana, Y. / Rodriguez-Bernal, C. / Sanfelix, G. / Peiro, S. et al. | 2018
-
PCV11 - MODELING CARDIOVASCULAR EVENT REDUCTION THROUGH LOW-DENSITY LIPOPROTEIN REDUCTION IN COST-EFFECTIVENESS ANALYSES: A META-REGRESSION APPROACHDi Tanna, G.L. / Villa, G. et al. | 2018
-
PCV1 - NERVOUS SYSTEM DRUGS AND RISK OF ISCHEMIC STROKE: A REAL WORLD DATA CASE-CONTROL STUDYGomez-Lumbreras, A. / Giner, M. / Marsal, J. / García-Sangenis, A. / Pera, H. / Morros, R. et al. | 2018
-
PCP61 - EVIDENCE-BASED VALUE OF PD-1 / PD-L1 INHIBITORS IN NSCLC: COMPARISON OF VALUE TO PRICEDoyle, J.J. / Wood, B. et al. | 2018
-
PCP53 - A DIAGNOSTIC FRAMEWORK TO EVALUATE REAL-WORLD DATA SOURCES FOR REAL-WORLD EVIDENCE GENERATIONDenysyk, L. / Doyle, J. / Sood, R. et al. | 2018
-
PCP55 - REVIEW AND RECOMMENDATIONS OF ENDPOINTS FOR REAL-WORLD STUDIES IN ONCOLOGYJulian, G.S. / Duva, A. / Santana, P. / Cavalcanti, H.E. / Ballalai, A.F. et al. | 2018
-
PCP56 - EARLY ACCESS PROGRAMS: RECOMMENDATIONS FOR REAL-WORLD DATA COLLECTIONStein, D. / Soni, M. et al. | 2018
-
PCP33 - COULD THE US ADMINISTRATION IMPOSE DRUG PRICE RAISES IN THE EUROPEAN UNION (EU)?Dabbous, M. / Rémuzat, C. / Dussart, C. / Toumi, M. et al. | 2018
-
PCP22 - KILL / REPLACE / REGULATE: MOLECULAR-LEVEL VIEW OF TREATING DISEASE, EMERGING SOLUTIONS AND IMPLICATIONS FOR THE FUTURE OF HEALTHCARESogokon, P. / Morrison, S. et al. | 2018
-
PCP18 - EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT: A MARKER OF HTA FAILURE?Pisarczyk, K. / Rémuzat, C. / Hajjeji, B. / Toumi, M. et al. | 2018
-
PCP5 - THE ECOLOGICAL AND SOCIAL COSTS AND BENEFITS OF INTERVENTIONS – USING THE PRODUCT CARBON FOOTPRINT IN VALUE ASSESSMENTMiltenburger, C. / Borgstrom, F. / Ortsater, G. et al. | 2018
-
PCP11 - ORGANISATIONAL MODELS AND OPPORTUNITIES FOR EFFICIENCY MEASURING IN HEALTH CAREAraja, D. et al. | 2018
-
PCP44 - IMPLICATIONS OF GENOME-DRIVEN ONCOLOGY ON EVIDENCE REQUIREMENTS FOR HEALTH TECHNOLOGY ASSESSMENTLeslie, I. et al. | 2018
-
PCN364 - EVALUATING PSYCHOMETRIC PROPERTIES OF UK EQ-5D-5L SCORING ALGORITHMS IN METASTATIC MERKEL CELL CARCINOMABharmal, M. / Hunger, M. / Schlichting, M. et al. | 2018
-
PCN365 - AN ASSESSMENT OF PATIENT REPORTED OUTCOME (PRO) CLINICAL TRIAL DATA REPORTING, SPECIFIC TO CHOLANGIOCARCINOMA (CCA)Bernarde, J. / Boxell, E. / Baldock, L. / Rylands, A.J. et al. | 2018
-
PCN304 - APPROPRIATE COMPARATOR IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MELANOMA – A DYNAMIC SITUATIONItalia, N. / Kossow, S. / Claes, A. / Templin, C. / Kulp, W. et al. | 2018
-
PCN318 - CONDUCTING AND REPORTING INDIRECT TREATMENT COMPARISONS: A CRITICAL APPRAISAL OF ONCOLOGY TECHNOLOGY APPRAISALSLangham, J. / Langham, S. et al. | 2018
-
PCN290 - USE OF PCR AS A SURROGATE PRIMARY ENDPOINT IN DRUG PIVOTAL TRIALS IN NEOADJUVANT EARLY BREAST CANCER IN EU: A PERSPECTIVE FROM REGULATORS AND PAYERSFonseca, A.F. / Deplazes, S.N. et al. | 2018
-
HT7 - A REVIEW OF EFFICIENCY OPINIONS OF FRENCH 'HAUTE AUTORITE DE SANTE' (HAS) IN THE ONCOLOGY FIELDGalasso, A. / Diaz A, Medina / Cotté, F. / Gaudin, A. et al. | 2018
-
CN5 - COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE CHEMOTHERAPIES FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE (≥50%) METASTATIC NON-SMALL CELL LUNG CANCER IN FRANCEChouaid, C. / Bensimon, L. / Clay, E. / Millier, A. / Lévy-Bachelot, L. / Huang, M. / Levy, P. et al. | 2018
-
CE3 - COST-EFFECTIVENESS OF DEMENTIA CARE MANAGEMENT ALONGSIDE A CLUSTER-RANDOMIZED CONTROLLED INTERVENTIONAL DELPHI TRIALMichalowsky, B. / Xie, F. / Kaczynski, A. / Hoffmann, W. et al. | 2018
-
AC4 - RETROSPECTIVE ANALYSIS OF INAPPROPRIATE MEDICATION PRESCRIPTION INDICATORS IN ELDERLY POPULATION IN ITALYGalimberti, F. / Casula, M. / Olmastroni, E. / Russo, V. / Piscitelli, A. / Orlando, V. / Menditto, E. / Tragni, E. et al. | 2018
-
AD4 - ARE PATIENT-REPORTED PERSISTENCE AND ADHERENCE TO TREATMENT FOR A CHRONIC DISEASE VALID OUTCOMES? AN EXAMPLE WITH OSTEOPOROSISSenay, A. / Perreault, S. / Delisle, J. / Morin, S.N. / Banica, A. / Laflamme, Y. / Leduc, S. / Mac-Thiong, J. / Ranger, P. / Rouleau, D. et al. | 2018
-
PCN322 - AN EXAMPLE OF RWE USED FOR HTA EVALUATION: ERLOTINIB RENEGOTIATION IN ITALYRecchia, A. / Gervasi, A. / Avitabile, A. / Greco, A. et al. | 2018
-
CN1 - VALIDATING SURVIVAL EXTRAPOLATIONS IN FIRST LINE TREATMENT OF RENAL CELL CARCINOMA USING LITERATURE-BASED CONDITIONAL SURVIVAL PROBABILITIESKlijn, S. / Hofstra, M. / Malcolm, B. / Johannesen, K.M. et al. | 2018
-
PHP205 - BARRIERS TO AND FACILITATORS OF THE APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT IN MEDICINE PRICING AND REIMBURSEMENT POLICIES IN INDONESIAWasir, R. / Irawati, S. / Makady, A. / Postma, M.J. / Goettsch, W. / Feenstra, T. / Buskens, E. et al. | 2018
-
PHP181 - HEALTH TECHNOLOGY ASSESSMENT OF ONCOLOGY THERAPIES IN SPAIN AND ITALY: KEY METRICS AND CONSIDERATIONSPrivolnev, Y. / Moore, R. / Sharma, K. et al. | 2018
-
PHP191 - EVALUATION OF THE RENEWED LIFE REFORM PROGRAM FOR WORKERS WITH PREMORBID METABOLIC SYNDROME, OVERWEIGHT AND OBESITY IN THE AMAZONAS ASSISTANCE NETWORK OF PERUVIAN SOCIAL SECURITYEspinoza, S. / Tafur, H. et al. | 2018
-
PHP180 - ACCESS AND VALUE OF HEALTHCARE INNOVATION IN LATIN AMERICAMartin de Bustamante, M. / Alfonso, R. / Boers Trilles, V. / Guarin, D.F. et al. | 2018
-
PHP173 - PHARMACEUTICAL PROCUREMENT IN UKRAINE: AN ANALYSIS OF NEW TRENDS IN IMPROVING ACCESS TO MEDICINESPiniazhko, O. / Zaliska, O. / Ilyk, R. et al. | 2018
-
PHP168 - TRUMP'S PLANS TO REDUCE DRUG PRICES: FROM THE CAMPAIGN TRAIL TO AMERICAN PATIENTS FIRSTDabbous, M. / Rémuzat, C. / Toumi, M. et al. | 2018
-
PHP175 - EVOLUTION OF THE HEALTHCARE EXPENDITURES BY SERVICES IN HUNGARY BETWEEN 2010 AND 2015Kovács, G. / Nogel, M. / Sebestyén, A. / Endrei, D. / Ágoston, I. / Csákvári, T. / Boncz, I. et al. | 2018
-
PHP157 - APETITE FOR ON PATENTS: COST OF PRESCRIBING SWITCHING IN GREECEManias, N.G. / Papadopoulos, K. / Stefanidou, Z. / Ollandezos, M. et al. | 2018
-
PHP140 - CURRENT CHALLENGES AND POTENTIAL SOLUTION FOR PRICING REGULATORY AND REIMBURSEMENT FRAMEWORK OF INNOVATIVE DRUGS IN EGYPTElMordy, B. / Fouad, S. / Elsisi, G.H. / Elmahdawy, M.D. et al. | 2018
-
PHP130 - SICK-PAY EXPENDITURES IN HUNGARY BETWEEN 2005-2016Kovács, G. / Nogel, M. / Sebestyén, A. / Endrei, D. / Csákvári, T. / Boncz, I. et al. | 2018
-
PHP135 - CHANGES IN THE NUMBER OF DENTISTS IN EUROPEAN COUNTRIES BETWEEN 2000-2015Elmer, D. / Endrei, D. / Ágoston, I. / Horváth, L. / Molics, B. / Németh, N. / Horváthné Kívés, Z. / Boncz, I. et al. | 2018
-
PHP120 - WHAT DO WE STAND TO LOSE? THE PROPORTION OF US-OWNED PHARMACEUTICALS ON AUSTRALIA'S PHARMACEUTICAL BENEFITS SCHEMEWeston, A. / Taylor, C. / Standfield, L. et al. | 2018
-
PHP115 - COMPARATIVE ANALYSIS OF THE MARKET PENETRATION OF PERSONALISED MEDICINE DRUGS UNDER THE CONDITIONS OF AMNOGFischer, T. / Bonduelle, D. / Antoni, B. et al. | 2018
-
PHP111 - EXPLORING THE LEVELS OF UNDERSTANDING OF PERSONALIZED MEDICINE AMONGST MEDICAL STUDENTS IN SARAJEVOHenic, H. / Music, E. / Mackic, M. / Hamzic, A. / Sofic, E. / Smailbegovic, E. / Čatić, T. / Jusufović, R. et al. | 2018
-
PHP87 - COULD THE FRENCH COHORT ATU PROGRAM BE THE MODEL EUROPE NEEDS TO HARMONIZE COMPASSIONATE USE PROGRAMS?Rivière, P. / Houzelot, D. / de Paz, B. / Salvignol, O. et al. | 2018
-
PHP74 - A REVIEW OF THE INFLUENCE OF INTERNATIONAL REFERENCE PRICING (IRP) ON LAUNCH SEQUENCING IN EUROPEMak, C. / Marshall, J.D. et al. | 2018
-
PHP33 - UNDERSTANDING THE JAPANESE POLICY INITIATIVES AND THE PATIENT CHARACTERISTICS OF RARE, INTRACTABLE DISEASESKIM, H.R. / Crawford, B. et al. | 2018
-
PGI45 - RELIABILITY AND VALIDITY OF A NEW PATIENT-REPORTED OUTCOME FOR GASTROPARESISCheng, R. / Barnes, C. / Zhou, K. / Morris, S. / Goyal, A. / Cole, J.C. et al. | 2018
-
PDB135 - THE BURDEN OF DIABETES MELLITUS IN TAIWAN BASED ON PATIENT-REPORTED OUTCOMESFang, H. / Chen, C. / Lin, H. / Tang, C. et al. | 2018
-
PDB123 - WHAT ARE THE MOST VALUED PATIENT OUTCOMES REGARDING MEDICAL CARE FOR FRENCH PATIENTS WITH TYPE 1 DIABETES? RESULTS FROM AN ONLINE PATIENT COMMUNITY (CARENITY.COM)Debroucker, F. / Delporte, L. / Ullmann, E. et al. | 2018
-
PHP347 - REGULATORY, POLICY AND OPERATIONAL BARRIERS TO OUTCOME-BASED RISK SHARING AGREEMENTS IN THE U.S. MARKET: OPPORTUNITIES FOR REFORMGoodman, C. / Villarivera, C. / Gregor, K.J. / van Bavel, J. et al. | 2018
-
PHP334 - PHYSICIAN-RELATED FACTORS IN DOCTOR-SHOPPING: A SYSTEMATIC LITERATURE REVIEWJaafer, N. / Biernikiewicz, M. / Toumi, M. et al. | 2018
-
PHP264 - QUALITATIVE ANALYSIS OF CLINICAL TRIALS RELATED TO DIABETES REGISTERED WITH CLINICAL TRIAL REGISTRY OF INDIABhat, B. / Dharmagadda, S. / Udupa, N. et al. | 2018
-
PHP241 - INSIGHTS FROM PREVIOUS ATMP ASSESSMENTS IN THE UNITED KINGDOM, GERMANY AND FRANCE FOR FUTURE CAR-T REVIEWSSchuurman, S.M. / Poeton, A.K. / Delaitre-Bonnin, C. et al. | 2018
-
PHP245 - UNDERSTANDING THE IMPACT OF REAL WORLD EVIDENCE ON REIMBURSEMENT DECISIONS ACROSS EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERSKumar Singh, K. / Clapton, G.S. / Rebelo de Sousa, C. / Tripathi, S. et al. | 2018
-
PHP236 - QUALITY OF EVIDENCE ON THE COST-EFFECTIVENESS OF DRUGS PROPOSED FOR THE INCLUSION IN THE RUSSIAN VITAL AND ESSENTIAL DRUGS LIST IN 2014-2017Bezdenezhnykh, T. / Omelyanovskiy, V. / Avxentyeva, M. / Sura, M. et al. | 2018
-
PDB61 - COST-EFFECTIVENESS ANALYSIS OF HUMAN OR ANALOGUE BASAL INSULIN-SUPPORTED ORAL THERAPY IN TYPE 2 DIABETES IN HUNGARYNémeth, T. / Tabák, Á / Bán, A. / Bacskai, M. / Tarcsa, M. et al. | 2018
-
PDB23 - THE CLINICAL GAP BETWEEN THE GUIDELINES AND PRACTICE OF STATINS PRESCRIBING AMONG DIABETIC PATIENTSHammad, M.A. / Syed Sulaiman, S.A. / Aziz, N.A. / Mohamed Noor, D.A. et al. | 2018
-
PDB21 - COMPARATIVE EFFECTIVENESS OF SGLT2 INHIBITORS IN TYPE II DIABETES DERIVED FROM AN OVERVIEW OF 55 SYSTEMATIC REVIEWSOrigasa, H. / Yotsutani, N. et al. | 2018
-
PDB51 - RESULTS OF THE COSMODIA STUDY: ESTIMATING THE IMPACT ON THE NUMBER OF CLINICAL COMPLICATIONS AND THE ASSOCIATED POTENTIAL FINANCIAL BENEFIT AS A CONSEQUENCE OF BETTER MANAGEMENT OF GLYCAEMIC CONTROL IN PEOPLE WITH TYPE 2 DIABETES IN SPAINMata-Cases, M. / Mahon, J. / Mauricio, D. / Franch-Nadal, J. / Real, J. / Hex, N. et al. | 2018
-
PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOMReifsnider, O. / Kansal, A. / Franke, J. / Lee, J. / George, J.T. / Brueckmann, M. / Kaspers, S. / Brand, S. / Ustyugova, A. / Linden, S. et al. | 2018
-
PDB28 - TYPE 2 DIABETES: CHANGING PATTERNS OF USE OF THE VARIOUS CLASSES OF ANTIDIABETIC DRUGS 8 YEARS AFTER STARTING TREATMENT: A NATIONWIDE COHORT STUDY USING THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)Aguade, A. / Gastaldi-Menager, C. / Karsenty, D. / Baudot, F. / Fontaine, P. / Fagot-Campagna, A. et al. | 2018
-
PDB1 - ACUTE RENAL OUTCOMES WITH SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS- REAL WORLD DATA ANALYSISMelzer Cohen, C. / Cahn, A. / Pollack, R. / Shalev, V. / Chodick, G. et al. | 2018
-
PCV141 - MEDICATION ADHERENCE AND POTENTIAL DETERMINANTS FOR NON-ADHERENCE IN YOUNG AND MALE PATIENTS AT CVD RISK IN KOREAChae, I. / Cha, J. / Kim, Y. et al. | 2018
-
PCV152 - TREATMENT BURDEN ASSOCIATED WITH DIFFERENT ANTICOAGULATION STRATEGIES OF ATRIAL FIBRILLATION PATIENTS: AN OBSERVATIONAL STUDY IN GERMANY, SWEDEN AND SWITZERLAND BASED ON THE ANTI-CLOT TREATMENT SCALEWilke, T. / Bloempott, S. / Henry, M. / Mueller, S. et al. | 2018
-
PCV110 - TREATMENT WITH FREE TRIPLE COMBINATION THERAPY OF ATORVASTATIN, PERINDOPRIL, AMLODIPINE AND ATORVASTATIN IN PATIENTS WITH HYPERTENSION: A REAL-WORLD POPULATION STUDY IN ITALY.Perrone, V. / Veronesi, C. / Degli Esposti, L. et al. | 2018